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DISCOVERY, CHARACTERIZATION, AND DEVELOPMENT OF SMALL 
MOLECULE INHIBITORS OF GLYCOGEN SYNTHASE 
The over-accumulation of glycogen appears as a hallmark in various glycogen 
storage diseases (GSDs), including Pompe, Cori, Andersen, and Lafora disease. Glycogen 
synthase (GS) is the rate-limiting enzyme for glycogen synthesis. Recent evidence suggests 
that suppression of glycogen accumulation represents a potential therapeutic approach for 
treating these diseases. Herein, we describe the discovery, characterization, and 
development of small molecule inhibitors of GS through a multicomponent study including 
biochemical, biophysical, and cellular assays. Adopting an affinity-based fluorescence 
polarization assay, we identified a substituted imidazole molecule (H23), as a first-in-class 
inhibitor of yeast glycogen synthase 2 (yGsy2) from the 50,000 ChemBridge DIVERSet 
library. Structural data derived from X-ray crystallography at 2.85 Å, and enzyme kinetic 
data, revealed that H23 bound within the uridine diphosphate glucose binding pocket of 
yGsy2. Medicinal chemistry efforts examining over 500 H23 analogs produced structure-
activity relationship (SAR) profiles that led to the identification of potent pyrazole and 
isoflavone compounds with low micromolar potency against human glycogen synthase 1 
(hGYS1). Notably, several of the isoflavones demonstrated cellular efficacy toward 
suppressing glycogen accumulation. In an alternative effort to screen inhibitors directly 
against human GS, an activity-based assay was designed using a two-step colorimetric 
approach. This assay led to the identification of compounds with submicromolar potency 
to hGYS1 from a chemical library comprised of 10,000 compounds. One of the hit 
molecules, hexachlorophene, was crystallized bound to the active site of yGsy2. The 
viii 
structure was determined to 3.15 Å. Additional kinetic, mutagenic, and SAR studies 
validated the binding of hexachlorophene in the catalytic pocket and its non-competitive 
mode of inhibition. In summary, these two novel assays provided feasible biochemical 
platforms for large-scale screening of small molecule modulators of GS. The newly-
developed, potent analogs possess diverse promising scaffolds for drug development 
efforts targeting GS activity in GSDs associated with excess glycogen accumulation. 
 
Thomas D. Hurley, Ph.D., Chair  
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A.  Glycogen  
1.  Function and localization 
Carbohydrate is one of the major energy sources for many forms of life. Glucose 
polymerization is a universal mechanism for carbohydrate storage in nature. Starch, a 
polymeric carbohydrate consisting of amylose and amylopectin, is produced by most green 
plants as an energy reserve1. Glycogen, on the other hand, is a multi-tiered branched 
polymer of glucose that serves as a major storage form for many prokaryotes and 
eukaryotes including archaea, bacterial, animals, and humans2.  
 The two main tissues for glycogen deposition in mammals are liver and skeletal 
muscle. Other tissues are also capable of synthesizing and storing glycogen, albeit at much 
lower levels usually. These additional tissue deposits include brain, heart, kidney, and skin. 
However, the physiological role glycogen plays in different tissue types varies. Liver plays 
an essential role in glucose homeostasis by converting stored glycogen to glucose for 
release when needed to support glucose-centric metabolism in the brain and erythrocytes3. 
In muscle, glycogen acts as an intracellular glycolytic fuel when energy demand rises, such 
as during extended muscle contraction or in response to the fight-or-flight reaction. Within 
the brain, glycogen is primarily found in astrocytes, where it can be metabolized to lactate 
as an energy substrate for neighboring cells4.  
Glycogen is not homogenously distributed inside cells. Subcellular localization of 
glycogen appears organelle-specific where it supports different functions. In skeletal 
muscle, three pools of glycogen have been identified; subsarcolemmal glycogen, 
intermyofibrillar glycogen, and intramyofibrillar glycogen5. These compartmentalized 
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glycogen deposits show distinct effects on muscle fiber function6. During deposition and 
depletion, it is reported that glycogen particles are tightly associated with smooth 
endoplasmic reticulum, which contains various enzymes required for glycogen 
metabolism7. Although glycogen is mostly found in the cytoplasm, it can also be found in 
mitochondria8,9 and in the nucleus10. Nuclear glycogen is believed to carry out various 
functions, such as providing a structural scaffold for nuclear assembly11,12, sequestration 
of critical kinases and phosphatases12, and as a carbon source for histone acetylation13.  
2. Structure  
As a highly branched glucose polymer, glycogen structure is optimized to function 
as an efficient fuel reserve. The linear polymerization of glycogen is mediated through the 
formation of α-1,4-glycosidic bonds, and branch points are produced through the formation 
of α-1,6-glycosidic bonds (Figure 1A). According to Whelan’s model, glycogen forms a 
fractal structure comprised of two categories of chain, the inner B-chains that possess two 
branches on each chain, and outer A-chains that are unbranched14,15 (Figure 1B). Chemical 
analysis of mammalian glycogen revealed each chain has an average of 13 glucose units, 
whereas the precise location of branchpoints on each chain is not clearly defined16. In this 
model, glycogen grows with a spherical shape consisting of a series of concentric tiers 
(Figure 1C). Mathematical modeling suggested that a full glycogen molecule has a 
maximum of 12 tiers with ~55,000 glucose residues, a molecular mass of 107 Da, and a 44 
nm average diameter2. Notably, the outermost tier of any molecule formed in this way 
contains 50% of total glucose residues that would be involved in regular synthesis-
degradation cycle15.  
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Figure 1. Glycogen structure. (A) Glycogen linear polymerization is achieved through the 
formation of α-1,4-glycosidic linkages, and branches are produced through the formation 
of α-1,6-glycosidic linkages. (B) The fractal structure of glycogen contains inner B-chains 
which possess two branches on each chain, and outer unbranched A-chains. The number 
shown represents different tiers. The circled “G” denotes glycogenin. (C) The spherical 
shape of a full-sized glycogen molecule. (D) The three types of glycogen structures (α- and 
β-granule and γ-particle) identified using transmission electron microscopy are shown. 
(Adapted from Roach et al.2, Melendez et al.15, and Prats et al.17)  
Each glycogen granule is associated with a number of regulatory proteins, and 
forms an organelle-like structure, which has been termed the glycosome. Analysis using 
transmission electron microscopy revealed there are three types of glycogen structures, 
namely α- and β-granule and γ-particle17. The γ-particle is an electro-dense 3 nm protein-
rich structure that is bound to the β-granule, which is the carbohydrate polymer described 
above. The β-granule is 20-30 nm of size, has a molecular mass of 106-107 Da, and is 
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considered a rapid energy source. The α-granule, mostly present in liver, is composed of 
several β-granules in a broccoli-like fashion via a protein backbone rich in disulfide bonds. 
The α-granule can be as large as 300 nm in diameter, 108 Da in molecular weight, and is 
considered a slow energy source (Figure 1D)17.             
The way glycogen is constructed offers several metabolic advantages. First, its 
polymeric nature combined with hydrogen bond formation between its hydroxyl groups 
and water ensures glycogen solubility, while minimizing elevation of the osmotic pressure 
in cells by sequestering glucose in a polymeric form. Secondly, the tiered structure of 
glycogen allows rapid glucose incorporation and degradation, making glycogen a robust 
and renewable energy source. Thirdly, such a relatively simple, fractal structure provides 
an evolutionarily efficient approach for the regulation of glycogen metabolism.          
3.  Metabolism and regulation 
Glycogen metabolism constitutes one of the key pathways in living cells regulating 
systemic carbon or energy allocation18. The synthesis and degradation of glycogen is a 
highly conserved, complex, and coordinated process. When glucose is transported into 
cells, it is first converted to glucose-6-phosphate (G6P) via hexokinase before it can enter 
one of several metabolic pathways; glycolysis, the pentose phosphate pathway, or glycogen 
synthesis. The synthetic pathway for glycogen begins with the reversible conversion of 
G6P to glucose-1-phosphate (G1P). Subsequent reaction of G1P with uridine-5'-
triphosphate (UTP) forms uridine diphosphate glucose (UDPG), the immediate glucosyl 
donor for glycogen biosynthesis19. Typically, the initiation of glycogen synthesis is 
mediated by glycogenin (GN), which acts as a primer for glucose polymerization through 
the self-glycosylation at Tyr194 residue20,21. However, a primer protein may not be strictly 
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required for polysaccharide chain elongation, as GN-/- mice still accumulated normal levels 
of glycogen in liver and brain, while in skeletal and cardiac muscle elevated glycogen (four 
to seven times higher) was observed22. In any case, once the initial chain grows to 6-17 
glucose residues, two key enzymes catalyze further chain elongation. Glycogen synthase 
(GS) lengthens linear chains through the progressive addition of α-1,4-linked glucose 
residues to the non-reducing end of the polymer, and glycogen-branching enzyme (GBE) 
catalyzes the intramolecular transfer of seven glucose residues to a C-6 hydroxyl group to 
produce α-1,6 branch points for further elongation23. The degradation of glycogen occurs 
in both the cytoplasm and lysosome. In the cytoplasm, glycogen breakdown is regulated 
by the coordinated action of glycogen phosphorylase (PYG) and debranching enzyme, 
resulting in the release of G1P and free glucose. In the lysosome, in contrast, α-glucosidase 
(GAA) catalyzes the complete hydrolysis of glycogen to free glucose (Figure 2)17. 
Figure 2. Glycogen metabolism. A simplified scheme of glycogen synthesis and 
degradation pathway. 1. Hexokinase; 2. Glucose-6-phosphatase; 3. Phosphoglucomutase; 
4. Glycogen synthase (GS); 5. Glycogen branching enzyme (GBE); 6. Glycogen 
phosphorylase (PYG); 7. Debranching enzyme; 8. Lysosomal α-glucosidase (GAA).  
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The regulation of glycogen metabolism is primarily mediated through hormonal 
control, including the actions of insulin, glucagon, and epinephrine. When blood glucose 
levels rise, pancreatic β-cells secret insulin that binds to insulin receptors (IR) on target 
cells such as liver, muscle, and adipose tissue, resulting in the activation of protein kinase 
B (PKB) in a phosphoinositide 3-kinase (PI3K)-dependent manner. These actions lead to 
the subsequent phosphorylation and inactivation of glycogen synthase kinase-3 (GSK3). 
Lower GSK3 activity leads to lower phosphorylation levels at the C-terminal regulatory 
sites of GS and activation of GS, which promotes glycogen biosynthesis24. The 
dephosphorylation of GS is mediated by forms of type 1 protein phosphatase (PP1), the 
catalytic domain of which is held in close proximity to the glycogen granule and GS by a 
family of glycogen targeting subunits, including protein-targeting-to-glycogen (PTG), 
which is effectively an indirect activator of GS25. Activated PKB also plays an important 
role in the translocation of glucose transporters (GLUTs) to the plasma membrane, 
facilitating glucose delivery into cells26,27. In contrast, when blood glucose and insulin 
levels fall during fasting, the glucagon secreted by pancreatic α-cells binds to the glucagon 
receptor which is a member of the G-protein-coupled-receptor (GPCR) family. Glucagon 
binding to its receptor in the liver activates adenylate cyclase that converts adenosine 
triphosphate (ATP) to cyclic adenosine monophosphate (cAMP), which activates protein 
kinase A (PKA). PKA phosphorylates phosphorylase kinase (PhK), which in turn 
phosphorylates and activates glycogen phosphorylase, and leads to net glycogen 
degradation28. Similar to glucagon, epinephrine can also activate the breakdown of 
glycogen through the binding of β-adrenergic receptor, another class of GPCR29. Notably, 
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glucagon mostly works in liver, whereas epinephrine mainly acts on muscle, and to a lesser 
extent, in the liver (Figure 3).  
 
Figure 3. Regulation of glycogen metabolism. A simplified scheme of regulatory pathways 
for glycogen metabolism. Insulin receptor (IR); Phosphotidyl inositol 3-kinase (PI3K); 
Protein kinase B (PKB); Glycogen synthase kinase-3 (GSK3); Glucose transporter 4 
(GLUT4); Glucose-6-phosphate (G6P); G-protein-coupled-receptor (GPCR); 
Phosphorylase kinase (PhK). (Adapted from Baskaran30)   
B.  Glycogen synthase 
1.  Classification 
 GS is the rate-limiting enzyme in glycogen biosynthesis31, and belongs to the super 
family of glycosyltransferases (GTs), a ubiquitous group of enzymes that catalyze the 
transfer of a sugar moiety from an activated sugar donor onto an acceptor. The enormous 
diversity of these enzymes arises from their exquisite specificity for both donors and 
acceptors. GTs are widely distributed in both prokaryotes and eukaryotes, where they 
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contribute to a broad range of biological functions including structural support, metabolic 
storage, and signal transduction. GTs have been classified into over 78 families based on 
amino acid sequence homology (denoted as GTX). However, based on available structural 
data (100 crystal structures), only 3 distinct structural folds have been found. These three 
folds are 1) the GTA fold consisting of an α/β/α sandwich that resembles a Rossmann fold, 
2) the GTB fold consisting of two Rossmann domains, and 3) a third unclassified fold that 
displays a different type of α/β/α sandwich. GS is further divided into two subfamilies 
within the GTB fold superfamily based on sequence identity and differences in regulatory 
responses. Specifically, bacterial and plant GS are categorized into the GT5 subfamily 
because they use adenosine diphosphate glucose (ADPG) as the donor, whereas animal and 
fungal GS are divided into GT3 subfamily since UDPG is the substrate and they are 
regulated by allosteric and post-translational mechanisms (Figure 4)32,33.  
 
Figure 4. Classification of GTs based on structural folds and the subfamilies of GS. Three 
superfamily of GTs with representative crystal structure in each family are shown. GTs are 
represented with cartoon models in green (α-helix)/yellow (β-sheet). Bound nucleotide 
sugars are represented with stick models. (Adapted from Breton et al.33) 
9 
For the research described in this thesis, I studied both human and yeast GS. In 
humans, there are two isoforms of GS, human glycogen synthase 1 (hGYS1) and human 
glycogen synthase 2 (hGYS2)34,35. These isoenzymes possess approximately 70% 
sequence identity at the protein level and display the greatest variation within the N- and 
C-terminal sequence extensions. The two GS isoenzymes are differentially expressed: 
expression of hGYS2 occurs exclusively in liver, whereas expression of hGYS1 occurs 
primarily in skeletal muscle but is also expressed in most other tissues. Similar to higher 
eukaryotes, Saccharomyces cerevisiae has two genes encoding GS, yeast glycogen 
synthase 1 (yGSY1) and yeast glycogen synthase 2 (yGSY2). The product of the yGSY2 
gene, yGsy2p, is the predominant isoform36. Additionally, the yGSY1 gene is expressed 
constitutively throughout the growth cycle, whereas yGSY2 gene is controlled by 
environmental signals such as nutrient deprivation and cell cycle regulation36,37.     
2.  Structure  
 Although a structure for a mammalian GS remains elusive, crystal structures of two 
eukaryotic enzymes are known, including Gsy2 from Saccharomyces cerevisiae38 and GS 
from Caenorhabditis elegans39. Subsequently, structures of GS in complex with different 
ligands such as G6P38, maltooctaose40, UDPG41, or its associated protein GN39 have been 
determined, providing more structural insight into GS and its interaction with substrates. 
The structures of GS obtained from these two systems demonstrated formation of a 
tetramer. The structure of one of the monomers with various bound ligands is shown in 
Figure 5A. The individual subunits contain two Rossmann-fold domains with an 
interdomain cleft that harbors the catalytic site. Within the C-terminal domain, a large 
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insertion of around 100 amino acids forms a two helical bundle that comprises much of the 
interface for tetramerization.  
The allosteric activator of GS, G6P, binds to a pocket beneath a regulatory α-helix 
near the tetrameric interface in the C-terminal domain, and forms extensive interactions 
with surrounding residues on more than one subunit38. The pocket is composed of six 
residues, including His286, Lys290, His500, Arg580, Arg583, and Arg587, all of which 
form hydrogen bonding interactions with the phosphate group. The glucose binding site is 
formed upon the binding of G6P which rearranges a disordered loop (residues 277-285). 
The glucosyl moiety is stabilized through hydrogen bonds formed with Gln283, Asn284, 
and His280 in the intersubunit surface (Figure 5B). Binding of G6P induces large scale 
conformational changes and enzyme activation as shown in Figure 6A and is discussed 
further in the following section. 
Multiple glycogen-binding sites were identified from crystal studies of yGsy2p in 
complex with maltooctaose, an 8-glucose polymer. These sites include one located in the 
N-terminus, two on the C-terminus, and an additional site in the interdomain cleft adjacent 
to the active site40. These sites distribute across the surface of the enzyme and are conserved 
across different eukaryotic species. Mutations of these surface sites decreased glycogen 
binding, enzyme catalytic efficiency, as well as glycogen accumulation in yeast cells40. 
Additionally, these glycogen-binding sites are proposed to serve distinct functions. For 
instance, site-1 and site-2 may provide a “toe-hold” mechanism to support tight association 
of GS with glycogen particle, whereas site-4 may be critical in positioning the non-
reducing end of glycogen during catalysis.    
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Figure 5. Crystal structures of GS. (A) An integrated structural model of GS based on 
crystal studies from S. cerevisiae and C. elegans. Each GS monomer contains two 
Rossmann fold domains with a linker region in between. The binding sites for UDP, G6P, 
glycogen (α1-4 Glcn), and GN (CeGN34) are shown. (Figure from Zeqiraj et al.39). (B) 
Cartoon representation of the G6P binding pocket (PDB: 3NB0). Individual subunits are 
colored either in green or magenta. G6P (cyan) and its interacting residues are represented 
with stick model.  (C) Stick representation of the UDP•G (magenta) binding pocket (PDB: 
4KQM). The dashed black lines represent hydrogen bond formation. 
Crystal structures of yGsy2p in complex with UDP•G were obtained, revealing the 
binding of UDPG in the interdomain cleft. Noncovalent interactions dominate UDPG 
binding in the active site. Specifically, the uridine is sandwiched between Phe480 and 
Tyr492. The O4 group of the uracil moiety is within hydrogen bond distance to the 
backbone amide nitrogen of Leu481. The 2’- and 3’-OH groups on the ribosyl moiety form 
hydrogen bonds with Glu517 and Thr514. The α-phosphate of UDP interacts with the 
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peptide nitrogen of Tyr513 and the sidechain hydroxyl group of Thr514, whereas the β-
phosphate forms hydrogen bonds with Arg320, Lys326, and Gly23. Additionally, both α- 
and β-phosphate form intramolecular hydrogen bonds with the sugar moiety. The glucosyl 
units form intensive interactions with surrounding residues, including His193, Asn269, 
Trp511, and Arg199 (Figure 5C).           
The primer protein for glycogen synthesis, GN, was determined to bind to a 
conserved surface on the N-terminal domain of GS42, an observation supported by the 
crystal structure of C. elegans GS in complex with a 33-residue region (301-333) of the C-
terminal tail of human GN39. This study provides a structural basis for the recruitment of 
GS to the GN initiation complex. Furthermore, reciprocal mutagenic studies on the 
interaction motif demonstrated the GS-GN association is required for glycogen production 
in vitro and in vivo39.   
3.  Relationship between structure and regulation 
The available enzyme kinetic data supports a three-state activity model for 
GS38,43,44. These states include low activity phosphorylated state, the intermediate 
dephosphorylated (or basal) state, and G6P-activated state. A commonly used value that 
expresses the activity state of GS is the ratio of GS activity in the absence of as compared 
to the activity in the presence of G6P as an index of the phosphorylation level of the 
enzyme, where the value can vary between 0 (highly phosphorylated and inactive state) 
and 1 (fully activated state)45. Typical values for the mammalian enzymes are 0.02 for the 
highly phosphorylated form and 0.4 for the basal form46.  
The manner in which G6P and phosphorylation regulate GS activity is controlled 
by a cluster of six regulatory arginine. These residues are conserved across all eukaryotes. 
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In yGsy2p, simultaneous mutation of the first three arginine residues 
(R580A/R581A/R583A, or R580A3) produced an enzyme that can neither be activated by 
G6P nor inhibited by phosphorylation. Mutation of the last three arginine residues 
(R587A/R589A/R592A, or R587A3) created an enzyme that could be inhibited by 
phosphorylation but could not be activated by G6P44. Conformations of these three activity 
states of yGsy2p have all been determined (Figure 6), yielding structural mechanisms 
underlying the differences among GS activity states. It turned out that substrate 
accessibility to the active site is mainly responsible for the level of enzyme activation. In 
its inhibited state, the phosphorylated residue Thr668 plays a dominant role in suppressing 
GS activity47. This is achieved through the interaction between the first two arginine 
residues (R580/R581) and the phosphate moiety, leading to the closure of catalytic cleft. 
In the dephosphorylated state, the last two arginine residues (R589/R592) function to 
prevent the collapse of the regulatory helices toward the interface due to an electric 
repulsive effect, creating a basal state enzyme with an active site that is 5.9º more open 
than the inhibited state43. The distance between the regulatory helices between subunits in 
the basal state is 12 Å. The tetrameric interface is formed by a coiled-coil domain 
containing α15-α16 (residues 365-431), and a 12-mer disordered loop linking the two 
helices (residues 401-412). The distance between the equivalent α15 helices between 
subunits is 21 Å. Binding of G6P promotes a large conformational transition that drives 
the enzyme into an activated state, as reflected by the 13.3º degree of openness between 
the two Rossmann folds38. This change is induced by the interaction of G6P with two of 
the arginine residues (R583/R587) situated in the middle of the cluster, promoting a 16 Å 




Figure 6. Comparison of the different activity-state structures of yGsy2p. (A) Cartoon 
representation of the inhibited state (R589A2) structure (PDB: 5SUL), the basal state 
(R580A3) structure (PDB: 3NAZ), and the G6P-activated state (PDB: 3NB0). The catalytic 
efficiency (denoted as Vmax/Km), and the degree of openness between the two Rossmann-
fold, are shown for each activity-state. (B) Cartoon representation of the regulatory helices. 
The distance between the equivalent α15 helices between subunits for each state structure 




helices are drawn toward each subunit to a distance of 5.5 Å, allowing the active site to be 
further opened. As a result, the enzyme catalytic efficiency, indicated by Vmax/Km, 
increased from 0.2 for the inhibited state, 6 for the basal state, to 12 for the G6P-activated 
state (Figure 6A and 6B)44. 
4. Catalytic mechanism 
 The molecular mechanisms for both GN self-glycosylation and GS catalytic 
reaction have been under investigation over the past two decades, although a consensus 
regarding whether such reactions are SNi- or SN2-based has not been reached. One view 
considers the glycosyl transfer event to be an SN2-based reaction, which requires double 
nucleophilic enzyme substitution and the formation of a discrete enzyme-intermediate 
covalent complex. Enzyme studies on hGYS1 identified a consensus sequence (E-X7-E) 
that is conserved across eukaryotic enzymes. Mutation of either of the glutamate residues 
led to almost complete reduction of enzyme activity. These conserved glutamate residues 
were proposed as the potential nucleophiles in GS enzymes49. However, kinetic and 
structural studies on many glucosyl transferases favor an SNi-based reaction in which one 
catalytic nucleophile on the donor molecule is capable of completing such reaction41,50,51. 
Briefly, in the SNi model, the donor sugar moiety is activated by the β-phosphate of UDP 
upon deprotonation of 1’-OH group, rendering the 4’-OH group of the acceptor molecule 
an attacking nucleophile. As a consequence, UDPG is hydrolyzed to UDP and glucose, 
with the latter being conjugated onto acceptors such as glycogen or the Tyr195 residue of 
GN (Figure 7). The SN1 mechanism involves the formation of a carbocation intermediate, 
which allows two different avenues for nucleophile attack, both of which, would invert the 
stereochemistry of the anomeric carbon. As a consequence, the SN1 process is not widely 
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accepted as the catalytic mechanism for glycosyl transferase enzymes that retain the 
configuration of the anomeric carbon.   
      
Figure 7. SNi-based catalytic mechanism for GS. Briefly, activation of the sugar moiety is 
initiated by the β-phosphate of UDP which deprotonates the 1’-OH group and forms an 
oxocarbenium-like intermediate. The 4’-OH group of the acceptor acts as an attacking 
nucleophile, resulting in UDPG hydrolysis to UDP and subsequent glucose transfer. 
C.  Glycogen and glycogen storage diseases  
 Abnormal glycogen metabolism is associated with a large family of diseases called 
glycogen storage diseases (GSDs) (Table 1)19,52. Typically, defects in enzymes directly 
involved either in glycogen synthesis or degradation are the major causes. For instance, 
proteins such as GS, GBE1, and glycogenin 1 (GYG1) are all glycogen biosynthetic 
enzymes, and their deficiencies lead to GSD0, GSD4, and GSD15, respectively. In 
addition, mutations of enzymes in glycogenolysis or glycolysis affect glycogen 
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degradation and glucose utilization, resulting in a wide variety of diseases ranging from 
GSD2-3 and GSD5-14. Nonetheless, mutations of indirect and/or regulatory proteins of 
glycogen metabolism also contribute to the pathogenesis of some types of GSD. Lafora 
disease (LD) is one representative in this category, since it is caused by mutations within 
either one of the two genes, EPM2A or EPM2B. Specifically, EPM2A encodes laforin, a 
dual specificity glycogen phosphatase; and EPM2B encodes malin, an E3-ubiquitin ligase. 
They function as a complex to modulate GS activity53 and translocation of GLUTs54 as an 
indirect means to monitor glycogen accumulation.    
Various phenotypical symptoms and clinical courses are associated with GSDs 
depending on disease types and tissue specificity. Although liver and muscle are the major 
locations for glycogen storage, disease manifestation is present widely. In many GSD 
cases, the condition of hepatomegaly (an enlarged liver) is found in patients due to hepatic 
metabolic disorder. Such a defect is always accompanying with hypoglycemia. Exercise-
induced intolerance, cramps, muscle weakness, and fatigue are typical symptoms in 
skeletal muscle. Cardiomyopathy and heart failure is associated with glycogen 
accumulation in cardiomyocytes. In addition, the peripheral and central nervous systems 
(CNS) and renal tubules also suffer from glycogen abnormalities. Besides, the defect of 
energy production and utilization exerts a deleterious effect to the whole body and leads to 
growth retardation. The fatal outcome, as demonstrated by death at early ages, is not 
uncommon in GSD patients.  
One interesting fact is that glycogen over-accumulation is characteristic in most 
GSDs. In Pompe disease (GSD2), the deficiency of GAA leads to lysosomal glycogen 
accumulation in many tissues including skeletal, cardiac, and smooth muscle55. In Cori 
18 
disease (GSD3) and Andersen disease (GSD4), defects in the glycogen debranching 
enzyme (AGL) and GBE1, respectively, result in the deposition of glycogen with abnormal 
structure and in abnormal amounts56,57. LD is a fatal progressive myoclonus epilepsy 
accompanied by neurodegeneration for which the presence of abnormal glycogen 
inclusions known as Lafora bodies (LB)58 are the hallmark. LBs are composed of poorly 
branched, hyperphosphorylated, and insoluble forms of glycogen that occur in neurons, 
muscle and other tissues59,60,61. A common finding with excess glycogen accumulation is 
an association with impaired autophagy and dysregulated mitochondrial metabolism. 
These derangements often lead to cell death and early-onset lethal, disease progression in 









Table 1. Human GSD types. 
Type Enzyme (gene) deficiency  Enzyme function Symptoms 
GSD0 Glycogen synthase 
(GYS1; GYS2) 
Rate-limiting enzyme in glycogen biosynthesis, which 
catalyzes the transfer of glucose from UDPG to glycogen. 
Occasional muscle cramping; Growth 
failure in some cases. 





Completes the final step in gluconeogenesis, which 
hydrolyzes G6P, resulting in the creation of a phosphate 
group and free glucose. 
Growth failure. 
GSD2   
(Pompe 
disease) 
Lysosomal α-glucosidase (GAA) 
 
Catalyzes the breakdown of glycogen in the lysosome.  Muscle weakness; Cardiomyopathy; 
Death by age ~2 years. 
GSD3      
(Cori disease) 
Debranching enzyme (AGL) Facilitates the breakdown of glycogen through 






Branching enzyme 1 
(GBE1) 
Adds branches to the growing glycogen molecule during 
glycogen biosynthesis. 
Myopathy and dilated cardiomyopathy; 





Glycogen phosphorylase (PYGM) 
 
The rate-limiting step in glycogenolysis, which 







GSD6       
(Hers disease) 
Liver glycogen phosphorylase 
(PYGL) 
Cleaves α-1,4-glycosidic bond to release G1P 
from liver glycogen stores. 
Growth retardation. 
GSD7     
(Tarui disease) 
Phosphofructokinase Catalyzes a key step in glycolysis by converting fructose-
6-phosphate to fructose 1,6-bisphosphate.  
Exercise intolerance, with pain, cramps 
and, occasionally myoglobinuria. 
GSD8 Hepatic Glycogen Phosphorylase 
Kinase (PYKL) 
Phosphorylates and activates glycogen phosphorylase for 
glycogen degradation. 
Hepatomegaly; Growth retardation; 
Hypertriglyceridemia, and fasting 
hyperketosis. 
GSD9 Phosphorylase kinase A key enzyme in triggering glycogen breakdown. Hepatomegaly; Growth retardation; 
Exercise intolerance, with pain, cramps.  
GSD10 Phosphoglycerate mutase 
(PGAM2) 
Catalyzes a step in glycolysis by converting 3-
phosphoglycerate to 2-phosphoglycerate (2PG).  
Exercise-induced muscle cramps and 
weakness; Myoglobinuria. 
GSD11 Muscle lactate dehydrogenase 
(LDHA) 
Involved in glycolysis, which catalyzes the inter-
conversion of pyruvate and L-lactate 
Fatigue, muscle pain, and cramps during 
exercise. 
GSD12 Aldolase A (ALDOA) A glycolytic enzyme that catalyzes the reversible 
conversion of fructose-1,6-
bisphosphate to glyceraldehyde 3-phosphate (G3P) 
and dihydroxyacetone phosphate (DHAP). 





GSD13 β-enolase (ENO3) Known as phosphopyruvate hydratase, catalyzes the 
penultimate step of glycolysis. 
Muscle pain; Exercise intolerance. 
GSD14 Phosphoglucomutase (PGM1) Catalyzes the interconversion of G1P and G6P. Hepatopathy; Growth retardation; 
Myopathy; Cardiomyopathy; Cardiac 
arrest. 
GSD15 Glycogenin 1 (GYG1) A key enzyme in glycogen biosynthesis. Muscle atrophy; Slowly progressive 
weakness over decades. 
LD        
(Lafora 
disease) 
EPM2A or EMP2B EPM2A encodes laforin, a phosphatase with 
polysaccharide-binding domain. EPM2B encodes an E3 
ubiquitin ligase called malin. Both involve in glycogen 
production.  
Myoclonic seizures; Neurodegeneration; 





D.  Glycogen and diabetes        
Diabetes is a group of metabolic diseases characterized by a high level of blood 
glucose. It is generally classified in one of two types, type I diabetes (T1D) which occurs 
when pancreatic β-cells undergo autoimmune destruction, and type II diabetes (T2D) 
caused by insulin insensitivity as well as insufficiency64. Altered glycogen metabolism is 
associated with both types of diabetes. T1D patients suffer from postprandial 
hyperglycemia and fasting hypoglycemia due to poor glycogen stores. Restoration of 
normal insulin and glucose levels rescued hepatic glycogen synthesis and glucose 
production65,66. In T2D cases, the defects in postprandial glycogen synthesis, impaired 
suppression of endogenous glucose production, and reduced glucose disposal are even 
more profoundly associated with the disease, such that even controlled hyperglycemic 
hyperinsulinemia cannot restore these functional deficits67. Such close association points 
to a complex interplay between abnormal glycogen metabolism and underlying diabetes. 
Several clinical case studies support a direct link between abnormal glycogen 
storage and diabetes. In one GSD1 patient with an inborn defect of the gluconeogenic 
enzyme glucose 6-phosphatase, hepatomegaly and kidney disease was observed due to 
glycogen buildup. The patient gradually developed uncontrolled diabetic complications 
such as hyperglycemia and fasting hypoglycemia in adolescence68. In another study, a 
GSD3 patient diagnosed at age of 18 showed no signs of glucose intolerance, but developed 
diabetes with severe postprandial hyperglycemia69. Although the exact molecular 
mechanisms for the development of diabetes in GSD patients is not clear, in both cases 
treatment with a GAA inhibitor, which blocks lysosomal glycogen degradation, has 
demonstrated therapeutic efficacy for improved glycemic control. Through physiological, 
 
23 
immunochemical, and genetic analysis in diabetic animal models, one group has proposed 
that excess glycogen accumulation due to impaired glycogen metabolism, rather than 
hyperglycemia per se, is causative of β-cell dysfunction in T2D62,70. This is further 
supported by the fact that under hyperglycemic conditions, diabetic mice were restored 
with normal β-cell mass and function by treatment with the glucose-lowering drug 
metformin, whereas control mice did not recover β-cell function62. It is still under 
discussion whether abnormal glycogen metabolism is the cause of β-cell dysfunction, but 
it is conceivable that T2D could be grouped as one type of GSD.  
E.  Glycogen and cancer 
 Cancer cells accumulate glycogen to promote survival, proliferation, and 
metastasis71,72,73,74. Several studies identified oncogenic pathways that lead to glycogen 
biosynthesis in cancers. Hypoxia upregulates the expression of PP1, GS, and GLUTs in a 
hypoxia inducible factor (HIF)-dependent manner75,76,77. The oncogene Rab25 was 
identified as a positive regulator of glycogen synthesis partially through the modulation of 
PKB, which inhibits GSK3 activity and in turn leads to GS activation78. Interestingly, 
glycogen breakdown enzymes, in both cytosolic (PYG) and lysosomal (GAA) pathways, 
are upregulated in cancer cells79. Such an impact on glycogen metabolism is believed to 
support several important functions for cancer cell growth. The most obvious explanation 
is that glycogen functions as the primary energy source for cancer cells in response to 
nutrient deprivation in the tumor microenvironment. Additionally, glycogen-derived 
glucose can enter the pentose phosphate pathway, and provide building materials for 
macromolecule biosynthesis to support proliferation. Glucose metabolism also plays a key 
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role in scavenging reactive oxygen species (ROS) under stressed conditions and promotes 
cell survival.  
 The fact that defective glycogen metabolism is associated with cancer progression 
indicates that targeting glycogen metabolism could be a novel therapeutic approach for 
cancer treatment. Genetic or pharmacological intervention of glycogen metabolism was 
explored in a few cancer studies. For instance, as described earlier, Rab25 promotes 
glycogen synthesis whose expression is upregulated in many types of human cancers, 
whereas knockdown of Rab25 led to reduced glycogen accumulation and consequential 
cancer cell death78. AGL, a glycogen debranching enzyme, was found to be a novel tumor 
suppressor in bladder cancer, since loss of AGL leads to rapid growth of bladder cancer 
cells80. The rate-limiting enzyme in glycogen degradation, PYG, was believed to be an 
oncogene due to its ability to supply glucose and sustain proliferation, as well as preventing 
premature senescence in cancer cells79. Therefore, inhibiting PYG activity with small 
molecules has been exploited for cancer treatment, and showed promising outcomes such 
as reduced tumor growth and cell cycle arrest81,82. Notably, the negative regulator of GS, 
GSK3β, has gained extensive attention for its attractiveness as a viable cancer target. 
GSK3β is serine/threonine kinase involving in various aspects of cellular activity including 
proliferation, differentiation, motility, and survival83. However, its role in tumorigenesis is 
controversial because in certain types of cancer, GSK3β functions as a “tumor-suppressor”, 
whereas in others as a “tumor-promoter”. Therefore, GSK3β chemotherapies have to be 




F.  Rationale of the thesis study 
1. Suppressing glycogen accumulation through inhibition of GS activity for the 
treatment of GSDs  
Currently, there are no effective treatments for GSDs that ameliorate all cellular 
and organ dysfunction. For example, in Pompe disease, the administration of a genetically 
engineered enzyme (i.e., enzyme replacement therapy, ERT) that rescues the defective 
GAA in peripheral tissues failed to reverse the neurological defects. Accumulating 
evidence suggests that suppression of glycogen accumulation through inhibition of GS 
activity represents an alternative, potentially effective strategy for therapeutic approach for 
treating GSDs where ERT may not provide a complete solution. For instance, mouse 
models of LD that lack either of the causative genes, EPM2A or EPM2B, recapitulate 
aspects of the GSD patient phenotype, in that they accumulate polyglucosan bodies and 
misfolded proteins, display increased endoplasmic reticulum stress, and show signs of 
neurodegeneration59, 63. Such animal models provided a venue for disrupting either PTG or 
GYS1 in these EPM2A(-/-) and EPM2B(-/-) knock-out mice as a mechanism for diminishing 
glycogen accumulation, LB formation, and the associated neurological and epileptic 
symptoms (Figure 8)84,85,86. Inhibition of GS activity via suppression of mTOR signaling 
also increases the effectiveness of treatments for Pompe disease in conjunction with ERT87. 
Moreover, a recent report has shown that GYS2 inhibition with RNAi prevents liver injury 
in mouse models of GSDs88. Although human clinical characteristics may vary from animal 
model phenotypes, the availability of these models and the appearance of promising 




The premise of this thesis study is that suppressing glycogen accumulation could 
alleviate the pathology of GSDs associated with excess glycogen accumulation. Our 
primary objective is to discover, characterize, and develop small molecule inhibitors of GS 
as a viable chemotherapeutic approach for treating GSDs. The molecules generated from 
this study can also be utilized as chemical probes for other disease applications, such as in 
diabetes and cancer, as described earlier.    
Figure 8. PTG or GYS knock-out mice alleviated LD pathology. (A) PTG deficiency 
suppresses LBs in brain (hippocampus) and muscle (gastrocnemius) of Epm2a-/- mice. (B) 
Epm2a-/- mice lacking Gys1 have no LB in the cerebellum, hippocampus, and skeletal 
muscle. [Panel A (Anna A. DePaoli-Roach and Peter J. Roach, unpublished results), panel 
B adapted from Pederson et al.85) 
2. The necessity of developing high-throughput screening assays against GS 
The traditional method to assess GS activity is through a radiochemical assay that 
measures 14C-glucose incorporation from UDP-[U-14C]glucose into glycogen89. 




Figure 9. An outline of the 14C-glucose incorporation assay protocol. This radiochemical 
assay features five main steps including incubation, transfer, washing, drying, and 
measurement. Experimental procedure and time consumption for each key step are shown.   
1) Add GS to tube #1 containing assay mixtures including glycogen, UDPG, G6P, 
and UDP-[U-14C]glucose, start timer. At 20 seconds interval, add GS to each 
remaining tube (#2-n). Total incubation time for enzyme reaction is 20 minutes.   
2) After incubation, transfer assay mix from tube #1 to filter paper #1, and then 
from each remaining tube (#2-n) to corresponding filter paper, again at 20 
seconds interval. Allow filter paper to absorb in assay solution briefly, and then 
place it into the wash beaker containing 66% ethanol.  
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3) Use ice cold ethanol in the first wash for 15 minutes, and another cold ethanol 
wash for 50 minutes, followed by a third wash at room temperature for an 
additional 15 minutes. 
4) Place papers on aluminum foil and let them dry under heat lamp for 15 minutes.  
5) Place each dried filter paper in separate vials, add scintillation fluid, and 
measure radioactivity with the scintillation counter. It typically takes a 5-minute 
measurement for each vial. 
As the standard activity measurement for GS, this assay involves appropriate safety 
measures for handling radioisotopes as well as multiple transfer and washing steps to 
remove residual substrates. The combination of laboratory effort, cost, safety, and waste 
disposal makes this radiochemical assay unsuitable for high-throughput screening (HTS). 
As a result, the development of alternative rapid, robust, and nonradioactive screening 
assays becomes necessary to initiate the discovery of small molecule inhibitors of GS. 
Herein, I report our efforts to develop two novel HTS assays for the identification of small 
molecule inhibitors of GS. In one assay, we synthesized a G6P-coupled fluorescent probe, 
and screened compounds that can displace the G6P-conjugated fluorophore using a 
fluorescence polarization (FP) assay. In another assay, GS catalytic activity is linked to 
inorganic phosphate production which is then detected though the use of the malachite 
green reagent. Both assays have been proven to be suitable for HTS with excellent Z'-
scores. We screened two chemical libraries using the FP assay as well as the coupled GS 
activity assay against 50,000 and 10,000 compounds, respectively. Primary hits were 
identified for subsequent characterization and development. 
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I used a number of biochemical and biophysical tools to characterize the hits, 
including enzyme kinetics, enzyme mutagenesis, and X-ray crystallography, through 
which I aimed to determine the mode of inhibition, binding affinity, and the structure of 
the ligand-enzyme complexes. Such information is utilized for structure-guided drug 
development and medicinal chemistry optimization through the development of structure-
activity relationships (SAR). For lead compounds with promising in vitro properties, 




























II. Experimental section 
A.  Material  
1. Reagents 
DI water was filtered with a MilliQ Ultra-Pure water system (EMD Millipore, 
Billerica, MA) prior to use. UDPG (Sigma U4625) concentration was determined via 
absorbance at 262 nm. Radioactive UDP-14C-glucose was purchased from Perkin Elmer 
(NEC403000MC). G6P (Sigma G7879) was prepared in 50 mM Tris, pH 7.8. Rabbit liver 
glycogen (Sigma G8876) was prepared by mixing an 8 - 10% (w/v) solution over a TMD-
8 ion exchange resin (Sigma M8157) for 1 hour and washed with water to elute glycogen, 
followed by at least two ice cold ethanol precipitations. Precipitated glycogen was collected 
by centrifugation at 5,000 rpm for 20 min at 4°C. Air-dried glycogen was diluted in water 
to a final concentration of 80 mg/ml and stored at -20°C. WST-1 cell proliferation reagent 
(ab155902) was purchased from Abcam. For the coupled malachite green HTS, a 2× assay 
master mix (800 µM G6P, 400 µM UDPG, 2 mg/mL glycogen, and 50 mM Tris, pH 7.8) 
was prepared in advance and stored in daily aliquots at -20°C. A second, 2× control assay 
mix was prepared identically to the 2× assay master mix but without G6P. 
2. Commercial chemical libraries and compounds 
Unless otherwise noted, most compounds were purchased from commercial 
chemical libraries. The 50K compound DIVERSet library, the primary hits H1-H110 
(Figure 15A), and analogs IM1-4, PR7-9 were purchased from ChemBridge Corporation 
(San Diego, CA). Analogs PR5, PR6 and PR10 were purchased from Vitas-M Laboratory 
(Champaign, IL) (Table 4). The purity of these purchased compounds were 95% based 
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on the spectra (either LC/MS or NMR) provided by the vendors. All pyrazoles, which were 
synthesized in house, were validated by both LC/MS and NMR.  
The 10K compound library was obtained from the Chemical Genomics Core 
Facility at Indiana University School of Medicine. The library consisted of drugs and 
natural products, including the LOPAC 1280 and Microsource Spectrum 2400, both 
consisting of drugs and bioactives, plus AnalytiCon’s 1000 compound MEGx of natural 
products and the 5000 compound NATx of semi-synthetic natural compounds.  
Compounds including hexachlorophene (45526), analogs HC1 (SML1440), HC2 
(COM448626140), HC3 (R579696), HC5 (35992), HC7 (93453), HC8 (IDF00128), 
HC10 (C44702), HC12 (113700), HC14 (B46808), HC15 (S926744) were purchased 
from Sigma-Aldrich. Analog HC6 (5222210) was purchased from ChemBridge 
corporation. Analogs HC4 (0352-0636) and HC13 (0089-0025) were purchased from 
ChemDiv Corporation. Analog HC9 (MFCD01763607) was from Maybridge Ltd. Analog 
HC11 (EN300-21338) was from ENAMINE Ltd (Table 7). According to the vendors, the 
purity of these compounds were >95%. All compounds were dissolved in 100% DMSO 
and stored at -20 °C. 
3. Compounds synthesized in house 
Synthesis of pyrazoles PZ11-30 was performed in a 3-step procedure that included 
1) synthesis of polyhydroxydeoxybenzoins; 2) ring-closure reaction for the synthesis of 
isoflavones with or without de-acetylation of phenolic groups; and 3) re-cyclization 
reaction of chromones in the presence of hydrazine90 (Scheme 1). Initial Hoesch reaction 
of substituted polyphenols and arylacetonitriles in boron trifluoride etherate with passing 
of anhydrous HCl led to formation of the A-ring polyhydroxylated deoxybenzoins I2-1 – 
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I2-5 and I2-9 – I2-1291. Alternative condensation of pyrogallol or 4-flouroresorcinol with 
phenylacetic acids in boron trifluoride etherate at heating was performed for the synthesis 
of 4’-hydroxy- or 4’-cyano deoxybenzoins I2-6 – I2-892. Ring-closure reaction with 
Vilsmeier reagent or trifluoroacetic anhydride in pyridine after work-up with water 
afforded the 2-unsubstituted or 2-trifloromethyl isoflavones. Synthesis of 2-methyl 
isoflavones I3-1, I3-2, I3-8, and I3-19 was performed by reaction of 
polyhydroxydeoxybenzoins with acetic anhydride in the presence of potassium acetate, 
with the subsequent deacylation in ethanol done without purification of the intermediate 
acetates. Target pyrazoles PZ11-30 (Table 4) were synthesized by reacting the synthesized 
2-(un)substituted isoflavones I3-1 – I3-20 with hydrazine hydrate in ethanol under reflux.  
B.  Methods  
1. HTS assays 
1.1 High-throughput FP assay  
1.1.1 Synthesis and purification of GlcN6P-fluorescein-5-Ex  
The tracer was synthesized by using a standard coupling reaction between an amine 
and N-hydroxysuccinimidyl ester. The reaction included: 100 mM NaHCO3 (pH 8.4), 130 
mM glucosamine-6-phosphate (GlcN6P) pH 8.0, 41.6% DMSO and 14 mM fluorescein-
Ex, succinimidyl ester. The reaction was incubated for 1 hour at 37°C followed by an 
overnight incubation at room temperature with continuous stirring, the reaction was 
stopped by addition of Tris-HCl (pH 8.0) to a final concentration of 0.2 M. Purification of 
GlcN6P-fluorescein-5-Ex was carried out by high-performance liquid chromatography 
(HPLC) on a semi-preparative Luna C18 column (250×10 mm, 5 μm) from Phenomenex. 
The eluents used were 25 mM NH4OAc (pH 5.5) (E1) and 100% methanol (E2). Elution 
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was performed by the following gradient: T0= 5% (v/v) E2, T10= 50% (v/v) E2, T30= 50% 
(v/v) E2, T45= 75% (v/v) E2, T55= 5% (v/v) E2 at a flow rate of 4 ml/min. The fractions 
containing the UV-containing fractions were collected, dried using a SpeedVac, dissolved 
in water and stored at -20ºC. The fractions containing GlcN6P-fluorescein-5-Ex were 
identified and confirmed by mass spectroscopy analysis. The final tracer concentration was 
determined by UV spectroscopy (Abs492~9.2 × 104 M−1 cm−1). 
1.1.2 FP assay 
All the FP experiments were performed on an EnVision multimode plate reader 
(Perkin Elmer) with the λex= 485 nm and λem= 535 nm. The FP experiments were performed 
in 384-well, black, flat-bottom microplates at room temperature. After addition of all 
reagents, plates were centrifuged for 1 minute at 1000g, followed by measurement of the 
FP signals, where each well was flashed 10 times and the average values were used. All 
polarization values were expressed as milli-Polarization units (mP), calculated from 
equation 1: 
 = 1000	 ∗ ∗∗                    (1) 
Where: S= fluorescence intensity measured when the excitation and emission polarizers 
are parallel and P= fluorescence intensity measured when the excitation and emission are 
perpendicular and G= grating factor that corrects for instrument bias. All the nonlinear 
regression analyses were performed by fitting the experimental data to the defined 
equations using SigmaPlot version 13.0. 
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1.1.3 Determination of the GlcN6P-fluorescein-5-Ex/yGsy2p equilibrium 
dissociation constant  
The concentration of the tracer was initially varied from 0-100 nM in order to 
determine the optimal assay concentration. Based on total fluorescence intensity and mP 
values, the optimal concentration was determined to lie between 10-40 nM in the final 
assay. The binding affinity for the tracer for yGsy2p was determined by adding the tracer 
to a final concentration of 20 nM to each well in the presence of varying yGsy2p 
concentrations (0 to 50 µM) in a final volume of 50 µL. The final assay buffer consisted of 
15 mM Tris-HCl (pH 7.8) and 15 mM NaCl, and the plate was incubated at room 
temperature for 10 minutes before reading. The dissociation constant Kd was calculated by 
fitting the experimental data to equation 2: 
 =  + ∗                    (2) 
Where  =mP, y0=mPmin, a= mPmax-mPmin, b= Kd and  = Concentration of yGsy2p. 
Experiments were performed in triplicate. 
1.1.4 Activation of yGsy2p or hGYS1 in the presence of G6P or GlcN6P 
The activation of hGYS1 or yGsy2p in the presence of G6P or GlcN6P was 
determined using the radiochemical assay previously described89 and the data was fit to 
equation 2. However, the parameters were defined as:  = % activation, y0 = % 
activationmin, a=% activationmax - % activationmin, = Concentration of G6P or GlcN6P and 
b= AC50. Experiments were performed in triplicate. 
1.1.5 Competitive displacement experiments 
G6P was serially diluted in 15 mM Tris-HCl (pH 7.8) to provide a final 
concentration ranging from 0.68 µM to 40 mM. The reaction mixture contained a final 
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concentration of 15 mM Tris-HCl (pH 7.8), 15 mM NaCl, 20 nM GlcN6P-fluorescein-5-
Ex, 4.2 µM yGsy2p and varying concentrations of G6P in a final volume of 50 µL. The 
plate was incubated for 10 minutes at room temperature before reading. The Kd was 
determined by fitting the observed mP changes to equation 3:  
1 = mP +  !	
"# $%&'()^+ ,,-,./0	
                    (3) 
Where 1= mP, EC50= Kd, = Concentration of G6P. Experiments were performed in 
triplicate. 
1.1.6 Determination of Z’-factor 
To determine the quality of the FP-displacement assay for adaptation for HTS, the 
Z′-factor was calculated using equation 4: 
12 = 1 − 4567689:;7;8:                     (4) 
Where σp and σn are the standard deviations of the signal for the positive and negative 
controls. 
For the negative control, 2 µL of H2O was added, and for the positive control, 2 µL 
of G6P was added to a final concentration of 2 mM in a 384-well plate. The protein sample 
was prepared in 25 mM Tris-HCl (pH 7.8), 25 mM NaCl, 7 µM yGsy2p, and 40 nM tracer, 
which was dispensed by a Multi-drop 384 liquid dispenser (Titertek) into the wells with 
either H2O or G6P. The plate was spun down in a centrifuge followed by measurement of 
the FP signals.  
1.2 High-throughput coupled GS activity assay  
For the HTS, each plate had three internal control sets: 1) Columns 1 and 2 were 
the positive control for the plate (n=32); 2) Column 23 was a no G6P control assay, serving 
as a substitute for the standard positive control for inhibition (n=16); and 3) Column 24 
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had no hGYS1 enzyme, representing the background measurement (n=16). Prior to the 
HTS, a Z’-factor was calculated with these three conditions, each at n ≥ 308, to determine 
the quality of the HTS for identifying hGYS1 modulators. All solutions were added using 
either the MultiFlo microplate dispenser (BioTek, Winooski, VT) or MultiDrop 384 
(TiterTek, Pforzheim, Germany). To the 384-well assay plates containing 10 µL compound 
solutions, 20 µL of the appropriate 2× assay mix was added to each well followed by 10 
µL of the hGYS1Δ634S8,11N enzyme (4 µg/ml) or enzyme dilution buffer. The final 40 
µL hGYS1Δ634S8,11N reaction assay solution contained 1 µg/ml hGYS1Δ634S8,11N 
enzyme, 200 µM UDPG, 400 µM G6P, 1 mg/mL glycogen, 0 or 12.5 µM compound 
(1.25% DMSO) and 25 µM DTT in approximately 50 mM Tris, pH 7.8. Column 23 
contained no G6P, while column 24 contained no hGYS1. The GS reaction was initiated 
by adding enzyme and was allowed to proceed at 30°C for 20 min, allowing approximately 
20% UDPG utilization in the positive controls. Next, the plates were added to a humidified 
chamber at >90°C for 15 minutes to inactivate GS activity. The humidified chamber 
consisted of a plastic wrapped Pyrex dish lined with paper towels and a thin layer of water, 
which was heated in a hybridization oven. Once the assay plates had cooled to room 
temperature, the second enzyme, hSCAN-1 (Provided by Terence Kirley), was added and 
the reaction incubated at 37°C for 60 minutes. Along with the components present for the 
GS reaction, the 50 µL hSCAN-1 reaction assay also contained 61.6 ng/mL hSCAN-1, 
0.01% Tween-20, and 5 mM CaCl2. To measure the amount of Pi produced, the Pi 
ColorLock Gold Assay Kit (Innova Biosciences, Cambridge, UK) was used as directed, 
with the exception that 10 µL of Gold mix (reagent + accelerator) was used instead of 12.5 
µL due to limitations of the liquid dispenser (Multidrop 384). Absorbance at 650 nm was 
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measured on a SpectraMax Plus 384 plate reader (Molecular Devices, Sunnyvale, CA). For 
the first round of screening, an activator was defined as having ≥140% activity compared 
to control (i.e., 40% activation), whereas an inhibitor had ≤75% activity compared to 
control (i.e., 25% inhibition). After one round of screening, compounds identified were 
rescreened twice using the same protocol. The cutoff value for activators remained at 
≥140% activity, but inhibitors were selected ≥40% inhibition.  
2. Expression and purification of yGsy2p and hGYS1 
The His-tagged yGsy2p recombinant enzyme was expressed in BL21 (DE3) 
Escherichia coli and purified using a two-step procedure including affinity 
chromatography on Ni2+-nitrilotriacetic acid-agarose, and ion exchange purification on a 
Q-sepharose column38. The hGYS1 expression clone in the pFL vector93 was modified by 
deleting the intein-chitin binding domain fusion at the C-terminus and replacing it with a 
simple non-cleavable 6×His-tag at the C-terminus. Purification of the construct was 
achieved using Ni-NTA resin (Qiagen product #31314) following the manufacturer’s 
instructions. Separately, a construct of hGYS1 was generated in which the C-terminus was 
truncated at position 634, and the N-terminal phosphorylation sites at positions 8 and 11 
were simultaneously mutated to Asn residues, which avoids solubility issues associated 
with mutation of these residues to Ala, in order to generate the hGYS1∆634S8,11N 
construct. This construct was also fused to the same C-terminal 6×His-tag for purification 
using Ni-NTA resin. 
3. Determination of kinetic parameters 
Enzyme activity of GS was determined using UDPG as a substrate through 14C-
glucose incorporation assay by monitoring the amount of radiolabeled glucose being 
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incorporated into glycogen89. Unless otherwise noted, yGsy2p activity was measured in 
reaction solution containing 0.3 mM UDPG in the absence or presence of 0.04 mM G6P. 
The activity of mutant hGYS1∆634S8,11N enzyme was measured using 0.2 mM UDPG 
and 0.4 mM G6P, while the activity of wild-type hGYS1 was measured using 0.2 mM 
UDPG and 1 mM G6P. All kinetic data analyses were performed using the program 
package SigmaPlot (version 13.0) by fitting the data to the appropriate kinetic equation. 
The IC50 curves for H23 and its analogs were fit to the four parameter logistic equation. 
Titration experiments for Michaelis-Menten curves were performed by covarying inhibitor 
and substrate concentrations. The reaction mixture contained 5 μg/ml yGsy2p, varied 
UDPG (0.2-8 mM in the absence or presence of 7.2 mM G6P) and H23 concentrations (0-
0.8 mM). All data were fit to competitive, noncompetitive and uncompetitive inhibition 
models in SigmaPlot (Version 13.0). An appropriate model was selected through analysis 
of goodness-of-fit and the residuals of those fits. All experiments include the controls 
contained 2% (v/v) DMSO. The values presented here are the averages ± the standard 
errors of the mean of three independent experiments with duplicate measurements for each 
data point in each experiment. 
4. Crystallization and structure determination 
The G6P-bound yGsy2p (wild-type) crystals were obtained using the hanging drop 
vapor diffusion method38. Briefly, the protein solution was prepared at 3 mg/ml in the 
buffer containing 20 mM Tris-HCl pH 8.0, 1mM β-mercaptoethanol, and 25 mM G6P. The 
protein solution was mixed with crystallization reservoir solution containing 0.1 M Bis-
Tris, pH 5.9 and 13-15% PEG300. The crystals were soaked with compounds on sitting 
drop plates to obtain inhibitor-bound yGsy2p complex. The crystals were cryo-protected 
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in the solution containing 0.1M Bis-Tris pH 5.9, 30% PEG300, and frozen in gaseous N2 
at 100K. Diffraction data sets were collected using X-ray crystallography at the Advanced 
Photon Source at beamline 19-ID, operated by the Structural Biology Center at Argonne 
National Laboratory. The data sets were then indexed, integrated and scaled using the 
HKL300094 program package. The structures were solved by molecular replacement using 
PHASER MR95, as implemented in the Collaborative Computational Project Number 496 
(CCP4) program suite. The G6P bound yGsy2p-R589/592A2 mutant structure (pdb code: 
3NB0) was used as the model for molecular replacement. The structures were initially 
refined with a single round of rigid body refinement for individual domains, followed by 
iterative rounds of restrained refinement with the application of domain-based TLS and 
NCS restraints using REFMAC597 as implemented in CCP4. COOT98 (version 0.7.2.1) was 
used to visually inspect and manually adjust the refined models. 
5. Analysis of GS activity from cell lysates 
HEK293-PTG cells were generated by transfecting HEK293 cells99 with the 
plasmid pCDH-FLAG-PTG, harboring the mouse PTG coding region and the hygromycin 
antibiotic resistance gene utilizing Lipofectamine following manufacturer specifications. 
Mixed clones were selected for ~10 days in the presence of 0.2 mg/ml hygromycin, 
expanded and stored in liquid N2. Analyses of protein expression, GS activity ratio in the 
absence and presence of saturating concentrations of UDPG (4.4 mM) and of G6P (7.2 
mM) and glycogen levels indicated that the protein was expressed, the GS activity ratio 
was increased 7-fold, from 0.02 in control cells to 0.15 in transfected cells, and that 
glycogen was increased by 90-fold. Quantitation of the expression of PTG was difficult 
because the basal levels were very low and undetectable under our conditions. 
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For lysate preparation the HEK293-PTG cells were cultured in 100 mm plates with 
5.5 mM αMEM, 10% FBS, 6 μg/mL penicillin, 10 μg/mL streptomycin, and 0.2 mg/ml 
hygromycin. Rat-1 cells were cultured in 100 mm plates with 25 mM DMEM, 10% FBS, 
6 μg/mL penicillin and 10 μg/mL streptomycin. Cells were grown for 3-4 days until 
confluency. Before harvest, the cells were washed twice with 5 mL ice-cold GS buffer (50 
mM Tris-HCl pH 7.8, 20 mM EDTA, 25 mM KF). Then, 400 μL of GS homogenization 
buffer (50 mM Tris-HCl pH 7.8, 10 mM EDTA, 2 mM EGTA, 100 mM NaF) with protease 
inhibitor (0.1 mM TLCK, 10 μg/ml leupeptin, 1 mM benzamidine, 0.5 mM PMSF, 1 mM 
Na3VO4) and β-mercaptoethanol (0.4%) plus Triton X-100 (0.2%) were added to each 100 
mm plate. Plates were frozen on liquid N2 and scraped. Then the lysates were transferred 
to 2 mL Eppendorf tubes, sonicated for 15 seconds twice on ice, and placed on nutator for 
10 minutes at 4 ºC. Protein concentrations were measured using the Bradford reagent. GS 
activity was initially measured with varying concentrations of the lysates. For monitoring 
the effect of small molecules on GS, HEK293-PTG cell lysates were diluted 10-fold while 
Rat-1 cell lysates were diluted 2-fold in homogenization buffer to achieve steady-state 
kinetics under the conditions we used in the 14C-glucose incorporation assay33. GS activity 
in cell lysates was measured in 50 mM Tris-HCl buffer at pH 7.8 with 6.7 mg/ml glycogen, 
and subsaturating concentrations of UDPG  (0.2 mM) and G6P (1 mM) in the absence or 
presence of 100 μM H23 and its analogues. All assays including the controls contained 2% 
(v/v) DMSO. 
6. Generation of the S26A and Y513L mutants of yGsy2p 
The point mutations S26A and Y513L in yGsy2p were performed using 
QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies). The mutants were 
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cloned into pET-28A yeast Gsy2p construct44 using forward primers 5’-G GTT GGT GGT 
ATT TAC GCC GTG CTA AAA TCG AAG GC-3’/5’-C TAC GAG CCT TGG GGT CTC 
ACA CCT GCA GAA TGT AC-3’ and their complements, respectively, and were 
confirmed by DNA sequencing using T7 or T7-ter primer sequence. The mutant proteins 
were purified exactly the same way as was yGsy2p. However, the yield was poor compared 
to WT protein. Additionally, the activity of Y513L mutant was ~10-fold lower than WT 
enzyme. The activity of the S26A mutant was 100-fold lower than WT enzyme. Kinetics 
experiments with Y513L and S26A mutants were performed under saturating G6P 
concentration (7.2 mM). 
7. Analysis of hSCAN-1 activity towards UDPG, UDP, UMP, and G6P  
High-performance anion exchange chromatography (HPAEC) was used to analyze 
hSCAN-1 activity on the components present in the HTS reaction mix: UMP, UDP, UDPG, 
and G6P. Concentrations similar to what would be present in the reaction mix were used: 
400 µM for G6P and 200 µM for UMP, UDP, and UDPG, all in 50 mM Tris pH 7.8. Three 
incubations were set-up for each component. The first contained no additional enzymes 
and served as the control. The second incubation contained the hSCAN-1 enzyme at a 
concentration twice that used in the HTS, but otherwise prepared in the same manner as 
used in the HTS. The third incubation contained calf intestinal alkaline phosphatase (CIAP, 
Fisher Scientific-1 U/µL), diluted 1:500 in a solution containing 1 mM MgCl2. The 
reactions were incubated at 30°C for 3 hours and terminated by boiling for 5 minutes. The 
solutions were passed through a centrifuge filter (Costar Spin-X, 8160), diluted 1:10, and 
25 µL aliquots were loaded onto a PA1 column for separation by HPAEC using a Dionex 
ICS 3000 instrument and a sodium acetate gradient. UDPG, UDP, and UMP were 
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performed as previously described100. For G6P, the starting mobile phase, eluent A, 
consisted of 100mM NaOH and eluent B was 100 mM NaOH and 1 M sodium acetate.  
8. Enzymatic assay for cellular glycogen measurement 
HEK293-PTG cells were grown in 100 mm plates with 5.5 mM αMEM, 10% FBS, 
6 μg/mL penicillin, 10 μg/mL streptomycin, 2 ug/ml puromycin and 0.2 mg/ml 
hygromycin. Rat-1 cells were cultured in 100 mm plate with 25 mM DMEM, 10% FBS, 6 
μg/mL penicillin and 10 μg/mL streptomycin. When plates reached confluency, cells were 
washed, trypsinized, and counted with a hemocytomer. Cells were then transferred to 96-
well CellBind plates with each well containing 35,000 cells. After 3 days, cells were 
starved to eliminate glycogen accumulation by culturing cells in medium without glucose 
for 48 hours. After restoring the glucose levels with addition of standard medium (5.5 mM 
αMEM for HEK293-PTG cells/25 mM DMEM for Rat-1 cells), there is a linear 
accumulation of glycogen over 6 hours, during which period test compounds (0.5% 
DMSO) were added to examine their ability of blocking glycogen synthesis. For 
determination of glycogen levels, cells were washed, fixed with methanol and incubated 
with amyloglucosidase to hydrolyze glycogen to free glucose. Glucose was then converted 
to G6P via hexokinase, followed by oxidation with G6P dehydrogenase and quantification 
of the resultant NADPH.  
9. WST-1 assay for cellular toxicity  
The WST-1 assay was used to measure compound cytotoxicity in HEK293-PTG 
cells. Similarly, cells were first grown in 100 mm plate and then transferred to 96-well 
CellBind white-wall plate with each well containing 12,500 cells. After 2 days, compounds 
diluted in serum- and antibiotic-free media were added to cells and incubated for 24 hours. 
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Four hours prior to the end of compound incubation, 2-(4-iodophenyl)-3-(4-nitrophenyl)-
5-(2, 4-disulfophenyl)-2H-tetrazolium (WST-1) was added to cells. Reduction of WST-1 
was quantified by measuring the absorbance of the dye at 450 nm using a microplate reader. 
The percentage of cell viability was calculated using equation 5, by comparing the 
compound-treated wells to the DMSO-treated vehicle controls after subtraction of the 
negative control (media + WST-1). 
% Cell viability = (Abssample−Absneg) / ( AbsDMSO−Absneg) × 100%                    (5) 
Where Abssample denotes the absorbance value of compound-treated samples, AbsDMSO 
denotes the absorbance value of DMSO-treated samples, and Absneg indicates the 











III. Discovery, characterization, and development of small molecule inhibitors 
from high-throughput FP assay 
A.  Results 
1. Development of high-throughput FP assay 
As an alternative to the 14C-glucose incorporation assay, our strategy for developing 
a high-throughput assay ideally sought to establish an assay that is sensitive, rapid, and 
inexpensive101. We would reserve the classical radiochemical assay as the “orthogonal” 
assay for subsequent studies of hits emerging from any screening assay systems. Assays 
that measure the extent of polarized light emitted from a fluorescently labeled tracer 
molecule – or fluorescence polarization – can meet such HTS requirements. An FP assay 
utilizes a fluorescently-labeled tracer molecule that binds to a protein target and thereby 
forms a complex that rotates more slowly in solution than the fluorophore alone and that 
leads to differences in the polarization of the emitted light. Incubation of the protein-
fluorophore complex with small molecules that displace the fluorescent tracer into solution 
  
 
Figure 10. Principle of FP assay. An FP assay features the binding of a fluorophore to a 
protein target (e.g., GS) that leads to slower complex rotational motion and light 
polarization. Displacement of the fluorophore, either through direct competition or 
allosteric regulation, results in faster fluorophore rotation and light depolarization. 
Compounds that cause a decrease of light polarization are identified as protein modulators.     
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thereby produces more of the faster rotating complex and causes relative depolarization of 
the emitted light. Using this assay system as a vehicle for HTS, we identified small 
molecules that reduce the FP signal as GS-interacting agents (Figure 10). 
The development of any FP assay involves the design and synthesis of a functional, 
fluorescent probe. Although G6P is a well-known, allosteric activator of GS, the selective 
coupling to what would be similarly reactive hydroxyl groups in G6P presented an 
synthetic challenge. Because glucosamine-6-phosphate (GlcN6P) also activates GS102 and 
possesses a single, reactive amine group at the 2’-position, its selection as a molecular 
probe on which to tag a fluorophore is an attractive alternative to G6P. In addition, close 
inspection of the Gys2p crystal structure with bound G6P38 indicates that the 2’-OH is 
solvent exposed and thus may not impede binding of the probe if this position is modified. 
Herein, we synthesized a fluorophore-modified GlcN6P (aka GlcN6P-fluorescein-5-Ex) 
using GlcN6P and the N-hydroxysuccinimidyl ester of fluorescein-5-Ex (Figure 11A), 
purified the fluorophore by HPLC and confirmed the expected molecular mass by mass 
spectrometry (MS) in which it displayed a M+H+ peak at m/z 735.1267 consistent with 
[C31H31N2O15PS + H]+ with calculated exact mass within acceptable limits (i.e., calculated 
m/z 735.1256) (Figure 11B). 
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Figure 11. Synthesis, purification, and validation of GlcN6P-fluorescein-5-Ex. (A) 
Schematic representation of the coupling reaction of Fluorescein-5-Ex, succinimidyl ester 
and GlcN6P to form GlcN6P-fluorescein-5-Ex. (B) The HPLC-purified product of 
fluorophore coupling reaction, GlcN6P-fluorescein-5-Ex, was confirmed by MS 
demonstrating m/z of 735.1267. (This data was generated by Dr. Vimbai M. Chikwana.)  
We next examined the binding of the GlcN6P-fluorescein-5-Ex probe to GS by 
adding the tracer to varying concentrations of yGsy2p to generate a saturation binding 
curve, which led to a calculated dissociation constant of 7.6 > 0.7 μM (Figure 12A). 
Furthermore, the competitive displacement by G6P (Kd = 70.9 > 3.6 µM) demonstrated 
that the tracer molecule bound to the G6P allosteric site (Figure 12B). In comparison, we 
determined yGsy2p activation by G6P using the standard 14C-glucose incorporation assay 
which yielded an AC50 of 98.1 > 3.1 µM (Figure 12C). We also tested the binding of 
GlcN6P-fluorescein-5-Ex and displacement by G6P using hGYS1. While the GlcN6P-
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coupled fluorophore and the fluorophore alone bound to hGYS1, G6P was unable to 
displace either compound, a finding that suggested nonspecific binding of the fluorophore 
to hGYS1. For this reason, we used yGsy2p and not hGYS1 for HTS. The high 
conservation of residues within the G6P allosteric site, the active site and overall protein 
sequence identity (~55%) between yGsy2p and hGYS1 supported the decision to use the 
yeast enzyme as a screening surrogate for the human enzyme (Figure 13). The robustness 
of the FP assay for HTS was assessed by determining the Z′-factor, a parameter reflective 
of both the signal dynamic range and data variability103. While the ideal Z′-factor is 1, a Z′-
factor between 0.5 and 1 is considered excellent and suitable for screening assays. The FP 
values for the positive controls (maximal binding, without G6P) and negative controls 
(fully displaced tracer, with G6P) were 109.23 ± 1.97 and 26.48 ± 1.93 (mean ± SD) from 
the 384-wells, respectively. The Z′-factor for this assay was determined as 0.86, indicating 














Figure 12. Development of FP assay for HTS. (A) Saturation binding isotherm for 
GlcN6P-fluorescein-5-Ex binding to yGsy2p. The binding affinity was determined by 
adding GlcN6P-fluorescein-5-Ex to a final concentration of 20 nM in the presence of 
varying yGsy2p concentrations (0 to 50 µM). Kd= 7.6 > 0.7 µM. Averages of triplicate 
assays ± SEM are shown. (B) Displacement of GlcN6P-fluorescein-5-Ex binding to 
yGsy2p by G6P. A mixture of yGsy2p and GlcN6P-fluorescein-Ex was added to various 
G6P concentrations (0.68 µM to 40 mM). Kd= 70.9 > 3.6 µM. Averages of triplicate assays 
± SEM are shown. (C) Yeast Gsy2p activation in the presence of varying concentrations 
of G6P. AC50 was determined as 98.1 ± 3.1 μM. Averages of triplicate assays ± SEM are 
shown. (D) Z′-factor determination: fluorescence polarization values of the bound (-G6P), 
and the free (+2 mM G6P) GlcN6P-fluorescein-5-Ex are shown, for the 16 rows with each 
row containing 12 columns of either the bound or free state. The graphs depict a 
representative experiment from at least three independent experiments. (This data was 






Figure 13. Sequence alignment of yeast and human GS. The overall sequence identity between yGsy2p and hGYS1 is around 55%. 
Residues that form the active site, including R320/F480/L481/Y492/E517 (shown in red box), and G6P binding site (Arg cluster, shown 
in blue box) are highly conserved across yeast and human species. The sequence alignment was generated using ClustalX. 
R320 
F480/L481   Y492   E517  Arg cluster 
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2. Hit identification and validation  
Dr. Vimbai M. Chikwana performed the HTS against the yGsy2p enzyme using the 
50K ChemBridge DIVERSet library at 10 μM concentration (Table 2). The HTS was 
adapted to the 384-well plate format using three columns for the DMSO negative controls 
and one column for the unlabeled G6P as the positive control, resulting in a total of 157 
screening plates. We used a Z’-score threshold of -1, corresponding to a separation of 3 
standard deviations between μc (means of the control DMSO signal) and μs (means of the 
library sample signal) as a cutoff (Figure 14). These standards produced 117 hits and an 
overall 0.23% hit rate. Initial stock availability led to re-ordering of 110 compounds   
 
Figure 14. 384-well plate layout for FP HTS. Each screening plate has one column for 
unlabeled G6P as the positive control, three columns for the DMSO negative controls, and 
20 columns for compounds. Z’-score threshold of -1, corresponding to a separation of 3 
standard deviations between μc (means of the control DMSO signal) and μs (means of the 
library sample signal), was chosen as a signal cutoff for hit selection. The 50K compounds 
from ChemBridge DIVERSet library were applied to 157 screening plates, resulting in the 




Table 2. FP HTS protocols. 
Category Parameter Description 
Assay Type of assay In vitro 
Target Gsy2p, Saccharomyces cerevisiae  
Primary measurement Detection of fluorescence polarization 
Key reagents Purified yeast synthase Gsy2p (3 μM), synthesized and purified fluorophore GlcN6P-fluorescein-5-Ex 
(20 nM)                                          
Assay protocol The  FP experiments were described in Methods 
Library 
 
Library size 50,000 
Library composition The Library is selected from ChemBridge’s EXPRESSPick. Collection stock of more than 480,000 
handcrafted compounds. 
Source ChemBridge Corporation 
Screen Format 384-well plate 
Concentration tested 10 μM, 1.2 % DMSO 
Plate controls 
 
For the negative controls 10 µL of DMSO (6%) was added and for the positive controls 10 µL of G6P 
was added for a final concentration of 2 mM to 40 µL reaction mixture in a 384-well plate.     
Reagent/compound 
dispensing system 





Detection instrument  EnVision® Multilabel plate reader (PerkinElmer) 
Post-HTS analysis Assay validation/QC Plate corrected individual Z’-scores  
Hit criteria 
 
Z’-score threshold of -1, equivalent to a separation of 3 standard deviations between μc (means of the 
control signal) and μs (means of the library sample signal) 
Hit rate 0.23% 
Additional assay(s) 
 
Hits were validated using standard 14C-glucose incorporation assay against yGsy2p, using 100 μM 
compounds in triplicate 
Confirmation of hit purity 
and structure 




(designated H1-H110) from ChemBridge and validation of their activity using the standard 
14C-glucose incorporation assay at 100 μM concentration. This approach validated 16 hits 
with greater than 40% inhibition of yGsy2p activity (Figure 15A). 
Since the yGsy2p enzyme was used as a screening surrogate for the hGYS1 
enzyme, I next examined if the 16 validated compounds were also active as inhibitors of 
hGYS1 activity. To accomplish this necessary confirmation, we redesigned the hGYS1 
construct to create a constitutively active enzyme through deletion of the C-terminal 
phosphorylation domain (residues 635-737) and through the substitution of the two N-
terminal phosphorylation sites (Ser8, Ser11) with Asn residues (designated 
hGYS1∆634S8,11N). Purification of this truncated form of GS in significant quantity led 
to an enzyme that exhibited an activation state of ~0.2, a ratio of GS activity in the absence 
of as compared to the activity in the presence of G6P as an index of the phosphorylation 
state of the enzyme45. Unlike the heavily phosphorylated, full-length enzyme produced in 
insect cells that had an activation state of <0.0193, this truncated form of GS was well suited 
for screening assays designed to look for inhibitors because the enzyme was neither overly 
inhibited by phosphorylation nor rendered insensitive to the effects of G6P. At a test 
concentration of 100 μM, only 1 hit, namely a substituted imidazole, (rac)-2-methoxy-4-
(1-(2-(1-methylpyrrolidin-2-yl)ethyl)-4-phenyl-1H-imidazol-5-yl)phenol (H23), 






Figure 15. Hit identification and validation. (A) In the FP assay, setting a Z’-score threshold of -1 gave 117 initial hits, out of which 
110 (designated H1-H110) were re-purchased and tested. The blue column represents the percentage of FP signal to control. The hits 
were screened at 10 μM in single measurement. The orange column is the percentage of yGsy2p activity to control measured through 
14C-glucose incorporation assay. The hits were tested at 100 μM. Averages of triplicate assays ± SEM are shown. (B) Percentage of 
hGYS1Δ634S8,11N activity to control measured through 14C-glucose incorporation assay. The hits were tested at 100 μM. Averages of 




3. Crystal structure of the H23-yGsy2p complex                                                                                          
There are no mammalian GS crystal structures, but the structures of two eukaryotic 
enzymes, namely yGsy2p from Saccharomyces cerevisiae38 and GS from Caenorhabditis 
elegans39 provide a basis for structural studies of our small molecule inhibitors. As 
previously described, yeast Gsy2p existed as tetramer in the crystal structure, and each 
subunit contained two Rossmann-fold domains with the catalytic site in the interdomain 
cleft38. In the crystal packing environment in crystals of the activated form of GS, one of 
the four subunits appeared 13.3º more closed than the other three subunits41. I successfully 
determined the crystal structure of the H23-yGsy2p (wild-type) complex to a resolution of 
2.85 Å (Table 3), and observed H23 binding in three of the four subunits, all of which 
corresponded to the more “open” domain subunits (Figure 16B). The structure showed 
H23 bound within the active site of GS in a location that overlapped with the binding site 
for UDPG (Figure 16C and 16D). Structural alignment of the R589/592A2·UDP complex 
to the WT·H23 complex using their Cα carbons generated an overall root mean square 
deviation of 0.36 Å, indicating a high degree of similarity. The binding of H23 to yGsy2p 
was mediated by hydrogen-bond formation between the phenolic hydroxyl group of H23 
and the nitrogen backbone of Leu481, hydrophobic π-stacking interactions of the 2-
methoxyphenol sandwiched between Tyr492 and Phe480, dynamic van der Waals 
interactions of the stilbene-like double bond with the side chains of Phe480 and Arg320, 
and additional van der Waals interactions of the N-methylpyrrolidine moiety with Tyr492, 






Table 3. Structural data and refinement statistics for H23-yGsy2p crystal. 
Data collection Refinement 
Space group I222 No. reflections 95326 
Cell dimensions  Rwork/Rfree 0.20/0.26 
a, b, c (Å) 192.3, 206.6, 205.0 r.m.s. deviations  
α, β, γ 90.0, 90.0, 90.0 Bond lengths (Å) 0.010 
Resolution 50-2.85 Bond angles (º) 1.44 
Rmerge 0.091 (0.766) Ramachandran plot  
Rmeas 0.100 (0.843) Preferred/Allowed (%) 99.01 
Rpim 0.040 (0.347) Outliers (%) 0.99 
CC1/2 0.999 (0.857) B-factors  
I/σ(I) 20.3 (2.0) Protein Chain A, 80.1; B, 83.7; 
C, 91.9; D, 94.6 Completeness (%) 99.7 (100) 
Redundancy 6.3 (5.5) Ligand (H23) Chain A, 100.9; C, 




Figure 16. Crystal structure of the H23-yGsy2p complex (PDB: 6U77). (A) Chemical 
structure of H23. (B) Ribbon diagram representation of the crystal structure of H23-
yGsy2p complex. H23 is represented by space-filling models in cyan, and binds to three 
subunits of yGsy2p which are colored differently. (C) The electron density for H23 prior 
to the inclusion of the ligand in refinement. The map shown is the original unbiased 2Fo-
Fc map contoured at 1 standard deviation. (D) Stick representation of the superposed UDP 
(purple) and H23 (yellow) structures and their interactions with the surrounding amino 
acids. 
4. Kinetic characterization of H23 
In a study of the inhibitory potential for H23 against yeast and human GS using the 
standard 14C-glucose incorporation assay, H23 exhibited IC50 values of 280 µM and 263 
µM in the absence and presence, respectively, of G6P for yGsy2p (Figure 17A). The 
similarity in IC50 values indicated H23 was not in direct competition with G6P. Under 
subsaturating G6P concentrations, the IC50 values of H23 against either 




17B). Even though the presence or absence of G6P did not impact H23 potency, the activity 
state of the human GS enzyme had a five-fold effect on the binding of H23.  
Figure 17. Kinetic characterization of H23. (A) Inhibition of H23 to yGsy2p in the absence 
or presence of G6P. (B) Inhibition of H23 to hGYS1Δ634S8,11N and hGYS1 wild-type. 
All IC50 curves represent one of three experiments performed using triplicate 
measurements for each condition, with mean ± SEM shown. (C) Michaelis-Menten curves 
fit to the competitive inhibition equation for varied H23 versus UDPG. H23 has a Ki of 
370 ± 30 µM in the presence of G6P and a Ki of 290 ± 20 µM in the absence of G6P. UDP 
is used as a positive control for competitive inhibition against varied UDPG for yGsy2p, 
which displayed a Ki of 350 ± 10 µM. The reported Ki values are the mean ± SEM from 
three independent experiments in duplicate. 
To understand the mode of H23 inhibition, I performed co-variation experiments 
by varying the concentrations of UDPG at different fixed concentrations of H23 and fitting 
the kinetic data against the equations for competitive, non-competitive, and uncompetitive 




with respect to varied UDPG for yGsy2p, with Ki values of 0.37 mM in the presence of 
G6P, and 0.29 mM in the absence of G6P. UDP displayed a similar competitive mode of 
inhibition with a Ki value of 0.35 mM (Figure 17C).  
5. Development of SAR for H23 analogs toward hGYS1 
The overall protein sequence alignment shows 55% sequence identity between 
yGsy2p and hGYS1. Because the amino acids in the binding site for H23, including 
Arg320, Phe480, Leu481, Tyr492, and Glu517 in yGsy2p, were completely conserved 
across yeast and human species (Figure 13), the structural information derived from the 
H23-yGsy2p crystal structure provided a useful guide for SAR studies focused on hGYS1. 
We examined a total of 491 analogs that shared at least 50% structural similarity with H23, 
and tested their activities against yGsy2p, hGYS1∆634S8,11N, and wild-type hGYS1 
using the 14C-glucose incorporation assay. My initial kinetic studies showed that a five-
membered, heteroaryl (HA) core with a phenyl group at the A1 position, and a second, 
vicinal phenyl group were essential elements of H23 (Table 4). Consequently, analog 
development modified the HA core, A1 and substructures at R1-R7 positions shown in the 
structure in Table 4. In this study, all H23 analogs possessed one of the following HA 
cores: imidazole (designated as HA1, IM), pyrrole (designated as HA2, PR) or pyrazole 
(designated as HA3, PZ). Active compounds appeared in structures with any of these three 
cores, but the most potent compounds had a pyrazole (HA3) scaffold. Commercial libraries 
were the source of HA1 and HA2 compounds in Table 4, and a three-step synthesis 





Scheme 1. Synthesis of pyrazoles PZ11-30. Reagents and conditions: (a) (i) 
arylacetonitrile, BF3⋅Et2O, HCl (gas), rt, 6-8 h, (ii) H+/H2O, 0.5-2 h; (b) (i) arylacetic acid, 
BF3⋅Et2O, 80-90 0C, 2 h, (ii) H2O; (c) (i) DMF, BF3⋅Et2O, POCl3, 50-60 0C, 2 h, (ii) H2O; 
(d) (i) Ac2O, KOAc, reflux, 8 h, (ii) H2SO4, EtOH, reflux, 0.5 h; (e) (i) (CF3CO)2O, 
pyridine, rt, 48-120 h, (ii) H2O; (f) N2H4⋅H2O, reflux, 0.5-6 h. (This synthetic work was 
performed in Dr. Mykhaylo S. Frasinyuk’s laboratory at NAS of Ukraine and Dr. David S. 
Watt’s laboratory at University of Kentucky.) 
We took a step-by-step strategy to modify positions in H23 to augment or diminish 
interactions with substituents between H23 and relevant residues in yGsy2p. Briefly, 
starting from the imidazole core (HA1), we determined that the R1 hydroxyl group that 
formed a hydrogen bond with the peptide nitrogen of Leu481 was essential to retain good 
inhibitory activity (i.e., compare H23 versus IM1 in Table 2). The addition of an extra 
methylene unit to the R7 chain eliminated inhibitory potential (IM4 versus IM3). In a 




at the R1 position (PR7 versus PR9 or PR10). Interestingly, substitution of a carboxyl 
group at the R7 position improved the potency to hGYS1 by 2-fold (IC50 values for H23 
versus PR7), a finding that suggested different conformational binding modes for H23 and 
7 for hGYS1. 
Because none of the analogs within the HA1 or HA2 series generated noteworthy 
improvements in potency, we explored a different set of compounds based on a pyrazole 
core (HA3). Within the HA3 series, my SAR studies demonstrated the importance of a 
hydrogen bond acceptor at the R1 position as displayed in the following order of potency: 
-OH > -NO2 > -CN > -F > -H > -Cl (i.e., PZ23 versus PZ27, PZ25, PZ19, PZ21 and 
PZ15). When a chlorine is present at the R1 position, adding a second chlorine substituent 
at the R2 position improved potency (PZ12 versus PZ11 or PZ14 versus PZ13 or PZ17 
versus PZ15). The most potent compounds in this series had a pyrogallol group at the R4-6 
positions, and the hydroxyl groups on this substituent conferred inhibition to GS even if 
the R1 position was non-optimal. For instance, PZ11 was 16-fold more potent than H23. 
Strikingly, the meta-hydroxyl group (R5) was critical to binding. Substitution of this 
hydroxyl group with hydrogen decreased potency significantly (PZ16 versus PZ15 or 
PZ28 versus PZ27). The SAR studies also indicated that substituents at the R7 position had 
an effect on activity in the following order of -CF3 > -H > -CH3 (PZ15 or PZ13 versus 
PZ11; PZ17 or PZ14 versus PZ12). In summary, analog development initiated from the 
substituted imidazole H23 led to a substituted pyrazole, namely 4-(4-(4-hydroxyphenyl)-
3-(trifluoromethyl)-1H-pyrazol-5-yl)pyrogallol (PZ23) that had an in vitro IC50 value of 



















For HA3 Scaffold, IC50(S) were determined using a cut-off of 70% activity to hGYS1. 
Compound PZ24 is an exception since it has a unique F at R3 position. NI: no inhibition, 
greater than 95% activity; ND: not determined. Values are the mean ± SEM from at least 
three independent experiments in duplicate. 
6. Kinetic characterization of compound PZ23 
In order to understand the molecular features of our most potent analog, compound 
PZ23, I examined the kinetic characteristics of its interaction with GS (Figure 18A). PZ23 
has a competitive mode of inhibition, with a Ki value of 1.31 ± 0.14 µM (Figure 18B). In 
light of the SAR and kinetic studies, we hypothesized that the binding of PZ23 to the active 
site of yGsy2p resembled the binding of H23 in the active site. In this model, the hydroxyl 
group at R1 position formed a hydrogen bond with the nitrogen backbone of Leu481. The 
three hydroxyl groups in the pyrogallol subunit formed hydrogen bonds with Thr514 or 
Glu517. Additional structural flexibility of hydrogen-bond formation depended on the 
relative position of PZ23 in the binding pocket. As my SAR study showed, the hydroxyl 




bond formation between Arg320 and the pyrazole ring may also strengthen binding, 
particularly when an electron-withdrawing trifluoromethyl group was present, and 
diminish binding when electron-donating methyl group was present in the same position 
in the pyrazole ring (Figure 18C).  
 
Figure 18. Kinetic characterization of PZ23. (A) Dose response curves for parent 
compound H23 and the most potent analog PZ23 against wild-type hGYS1. (B) Michaelis-
Menten curve of competitive inhibition for PZ23 versus UDPG. PZ23 shows a Ki of 1.31 
± 0.14 µM under the tested condition. Ki value for PZ23 is the mean ± SEM from three 
independent experiments performed using duplicate measurements for each condition. (C) 
Hypothetical binding model of PZ23 to GS in the active site. Manual docking of PZ23 in 
the active site was performed based on SAR and mode of inhibition studies. (D) Validation 
of PZ23 binding in the active site. PZ23 showed decreased potency against the active-site 
mutant Y513L compared with wild-type yGsy2p. All IC50 curves represent one of three 
experiments performed using triplicate measurements for each condition, with mean ± 




To validate whether compound PZ23 bound within the active site as modelled, I 
substituted Y513 with L513. This substitution, Y513L, did not abolish GS activity. Unlike 
other active site mutations that almost completely eliminated enzyme activity, the Y513L 
mutant decreased GS catalytic activity by only 10-fold. Consistent with my modelled mode 
of binding, I found that inhibition by PZ23 toward Y513L was compromised compared to 
wild-type (Figure 18D).  
7. Inhibition of GS activity in cell lysates 
I next examined whether H23 analogs could inhibit GS activity in cell lysates. 
Cultured cells normally do not accumulate large amounts of glycogen, largely due to the 
high levels of phosphorylation and the resulting low activity state of GS53. Lysates from 
two cell lines were prepared for GS activity measurement: the HEK293-PTG 
overexpressing PTG, a regulatory subunit of PP1, that recruits the phosphatase to glycogen 
where it promotes the dephosphorylation and activation of GS104,105, and glycogen 
accumulation; and the Rat-1 fibroblasts which have detectable GS activity and glycogen as 
previously described106,107. The HEK293-PTG cells have a seven-fold increase in the GS 
activity ratio from 0.02 to 0.15. To determine GS activity in lysates and optimize the 
conditions for measurement, I measured the incorporation of 14C-glucose into glycogen at 
0.2 mM UDPG and 1 mM G6P initially as a function of different lysate concentrations. I 
observed a linear increase in GS activity within the range of 0.075-1.5 mg/ml lysate. Under 
the conditions of the assay, the lysate from the HEK293-PTG cells had 10-fold more 
activity than the Rat-1 cell lysate (Figure 19A). To limit substrate utilization to under 10%, 
I used 0.15 mg/mL HEK293-PTG lysate and 0.75 mg/mL Rat-1 lysate with imidazole H23, 




and PR7 did not significantly inhibit GS activity in lysates. However, the remaining four 
substituted pyrazoles, namely PZ15, PZ19, PZ27 and PZ23, reduced synthase activity in 
both HEK293-PTG and Rat-1 cell lysates by >30%. Consistent with its greatest potency 
toward purified enzyme, PZ23 exhibited almost complete inhibition of synthase activity in 
lysates (Figure 19B). In summary, these analogs targeted GS activity in the context of the 
glycogen particles present in cellular lysates with potencies similar to those observed in 
purified enzyme preparations. 
 
Figure 19. Inhibition of GS activity in cell lysates. (A) Synthase activity in HEK293-PTG 
and Rat-1 cell lysates in the presence of 0.2 mM UDPG and 1 mM G6P. The data was fit 
to linear regression line with equations showing synthase activity rate (nmole/min, y-axis) 
under various lysate concentrations (mg/ml, x-axis). The data represent averages of 
triplicate assays ± SEM. (B) Percent of 14C-glucose incorporation to control (DMSO) by 
cell lysates and recombinant hGYS1 in the presence of H23 and its analogs. For cell lysates 
and recombinant hGYS1, 100 μM and 20 μM compounds were used respectively. Averages 
of triplicate assays ± SEM are shown. 
8. SAR for isoflavones toward hGYS1 
In a three-step synthetic procedure, pyrazoles were made by the recyclization 
reaction of isoflavones with hydrazine hydrate (Scheme 1). A close inspection of the 
chemical structures of isoflavones and pyrazoles revealed their structural similarity with 




scaffold. Nonetheless, I examined the inhibitory potential of those precursory isoflavones 
to hGYS1 using the 14C-glucose incorporation assay. Strikingly, a number of isoflavones 
demonstrated low micromolar potency toward wild-type hGYS1, an observation 
comparable to the effect of their counterpart pyrazoles.  
Therefore, I performed SAR studies to determine the substructures within the 
isoflavone (IF) scaffold for their inhibitory effects against wild-type hGYS1 (Table 5). 
Based on the availability of our in-house synthesized compounds and commercial stock, I 
examined substructures at R1-5 positions. Notably, the isoflavone scaffold was prioritized 
with a hydroxyl group at the R1 position, and showed the order of potency as follows: -OH 
> -H > -F > -NO2 > -Cl > -CF3 > -OCF3 (IF9 versus IF5, IF12, IF29, IF15, IF33 and 
IF36). As the synthetic precursor of PZ23, which possesses the most potent inhibition 
among the pyrazole series (Table 4), IF9 appears as the best isoflavone inhibitor, with an 
IC50 value of 1.56 µM toward hGYS1. However, unlike the pyrazole scaffold which prefers 
a hydrogen bond acceptor, R1 position in isoflavones does not require this interaction. In 
contrast, a substituent that can function both as a hydrogen bond acceptor and a hydrogen 
bond donor seems to confer better inhibition (–OH in IF9 versus –NO2 in IF29). 
Variability at R2-3 is achieved via placement of chlorine at these two positions, but the 
impact on potency is negligible (IF12 versus IF26 or IF15 versus IF20, IF23). At the R4 
position, the electron withdrawing –CF3 group produces the best inhibition, whereas the 
electron donating –CH3 group generates the least inhibition (IF5 versus IF1, IF4 or IF12 
versus IF10, IF11 or IF15 versus IF13, IF14), an observation consistent with the effect of 
substructures flanking the pyrazole ring. Interestingly, the R5 position can only tolerate a 




structures such as ethylmorpholine or ethylpyrrolidine abolished inhibition under the assay 
condition (IF1 versus IF3 or IF5 versus IF6 or IF15 versus IF16, IF17).  






NI: no inhibition; ND: not determined. Values are the mean ± SEM from at least three 
independent experiments in duplicate. 
9. Kinetic characterization of isoflavones 
 To understand the mode of inhibition of isoflavones toward hGYS1, I chose IF1 as 




an approximate hill-slope value of -1, whereas other compounds showed cooperativity in 
the dose response assays (Table 5). Similar to H23 and PZ23, IF1 appears as a competitive 
inhibitor versus UDPG, with a Ki value of 13.2 µM, similar to its 10 µM IC50 value (Figure 
20A). Additionally, mutagenic studies using two active site mutants Y513L and Y513F on 
yGsy2 showed reduced IF9 potency to the mutant enzymes, compared with its potency to 
wild-type yGsy2 (Figure 20B). Furthermore, I examined whether active site accessibility 
affects compound inhibitory potential. Here, I utilized two active-state mutants, the 
R580A3 basal-state state mutant and the R589A2 inhibited state mutant. In the absence of 
G6P, IF9 displayed IC50 values of 11.0 µM, 16.1 µM, and 19.9 µM toward R580A3, wild-
type, and R589A2 mutants, respectively. In the presence of G6P, IF9 showed an IC50 value 
of 11.3 µM, resembling the effect toward basal state R580A3 mutant (Figure 20C). These 
data suggest that greater active site accessibility confers better potency for IF9. Based on 
the previous SAR study and my kinetic data, we proposed a model for the binding of IF9 
in the active site of GS. In this model, the R1 hydroxyl group forms a hydrogen bond with 
Leu481. The R4 position is prioritized with electron-withdrawing –CF3 group, possibly to 
facilitate an additional hydrogen bond formation between the oxygen element and Arg320. 
Furthermore, the hydroxyl group at R5 position appears to be critical to interact with residue 
Tyr513, since either loss of this hydroxyl group or mutation of Tyr513 to leucine or 





Figure 20. Kinetic characterization of isoflavones. (A) Michaelis-Menten curve of 
competitive inhibition for IF1 versus UDPG. IF1 shows a Ki of 13.2 ± 2.1 µM under the 
tested condition. Ki value for PZ23 is the mean ± SEM from three independent experiments 
performed using duplicate measurements for each condition. (B) Dose response curves for 
IF9 against wild-type, Y513L, and Y513F yGsy2 enzymes. (C) Dose response curves for 
IF9 against wild-type, R580A3, and R589A2 yGsy2 enzymes, either in the presence or 
absence of G6P. (D) Hypothetical binding model of IF9 to GS in the active site. Manual 
docking of IF9 in the active site was performed based on SAR and kinetic studies. All IC50 
curves represent one of three experiments performed using triplicate measurements for 
each condition, with mean ± SEM shown.  
10. Cellular glycogen accumulation 
 I next considered whether these low micromolar inhibitors for the two chemical 
scaffolds, i.e., pyrazoles and isoflavones, would suppress glycogen accumulation in cells. 
However, cultured cells normally do not accumulate large amounts of glycogen. Here, we 




HEK293-PTG cell line. The PTG gene is known to increase glycogen accumulation in cells 
and in mice by recruiting PP1 to glycogen where it can facilitate the dephosphorylation 
and activation of GS104,105. The HEK293-PTG overexpressing cell line has an enhanced 
GS activity ratio (indicative of active enzyme), and significantly increased levels of 
glycogen compared with non-transfected HEK293 cells. We utilized a starvation-refeeding 
protocol to examine the ability of the compounds to alter cellular glycogen accumulation. 
In brief, cells were first starved in no-glucose DMEM medium for 48 hours, during which 
period cellular glycogen stores are almost completely depleted. Then glucose-containing 
αMEM medium (5.5 mM) was refed to cells for another 6 hours. Meanwhile, compounds 
were added upon refeeding and incubated with cells for 6 hours. Since compounds were 
added after starvation and at the same time of refeeding, this assay directly evaluated the 
ability of compounds to inhibit glycogen re-synthesis. First, I validated whether this assay 
protocol is effective of identifying compounds that alter glycogen metabolism. I utilized as 
a positive control the widely-used glucose lowering T2D drug, metformin, which is known 
to inhibit glycogenesis and gluconeogenesis108. As shown in Figure 21A, metformin 
demonstrated dose-dependent inhibition of glycogen accumulation in HEK293-PTG cells 
with an EC50 of 9.9 mM, an observation consistent with its high working concentrations 
examined in various physiological conditions109,110,111. With the validation of this cellular 
glycogen assay, I next examined whether H23 analogs developed in Table 4 could 
suppress glycogen accumulation at a single dose of 25 μM. Interestingly, none of these 
molecules showed any inhibition of glycogen amount (Figure 21B). I also examined a 
number of isoflavones described in Table 5 for their cellular efficacy. Surprisingly, I found 






Figure 21. Screening of compounds for glycogen accumulation in HEK293-PTG cells. (A) Test of metformin using the starvation-
refeeding protocol. Metformin showed cellular efficacy of suppressing glycogen accumulation with an EC50 value of 9.9 ± 5.5 mM. (B) 
Screening of representative imidazole, pyrrole, and pyrazole compounds at a single dose of 25 µM in cells. (C-G) Screening of 
isoflavones at a single dose of 25 µM in cells. Data for efficacious compounds, including IF15 (C), IF20 (D), IF23 (E), IF29 (F), IF30 







of glycogen accumulation at 25 μM. Notably, all of these compounds possess a –CF3 group 
at R4 position, whereas their counterpart analogs with a –H or –CH3 group at R4 position, 
did not show any cellular effect (Figure 21C-G). The cellular efficacy of these 5 
isoflavones was further validated through dose response experiments, with compounds 
being incubated in cells for 6 hours (Figure 22A). To see if longer time treatment triggers 
more profound inhibition, I dosed the cells with compounds for 24 hours. The results 
showed more significant inhibitory effect of glycogen storage when the isoflavones were 
incubated for longer time in cells (Figure 22B). Taken together, these data identified five 
isoflavones as efficacious compounds bearing cellular efficacy of suppressing glycogen 
synthesis in a dose- and time-dependent manner. 
 
Figure 22. Concentration-dependent response for selected isoflavones in HEK293-PTG 
cells. Compounds were incubated in cells for 6 hours (A) or 24 hours (B). The data 
represent averages of triplicate assays ± SEM. 
11. Cellular toxicity assay 
Live cells normally maintain a reducing environment that can convert the stable 
tetrazolium salt WST-1 to its soluble form formazan through a complex cellular 




This bioreduction process is accompanied by the color change of yellow WST-1 to purple 
formazan, which can be quantified through colorimetric measurement as a reflection of 
viable cells present. Using this WST-1 assay, I measured cellular toxicity of metformin and 
the five isoflavones in HEK293-PTG cells incubated for 24 hours. Metformin did not show 
any cytotoxicity until concentration went up to 50 mM which showed ~75% cell viability, 
and 100 mM which showed ~35% cell viability (Figure 23A). For isoflavones, at 25 µM, 
IF36 caused around 50% cell death, whereas none of the other isoflavones (i.e., IF15, 
IF20, IF23, and IF29) did showed any noticeable changes in cell viability. However, all 
compounds demonstrated cellular toxicity at 50 µM and 100 µM concentrations (Figure 
23B). Since the isoflavones demonstrated a profound effect of suppressing glycogen 
accumulation at 25 µM within 6-hour treatment, we suggest that their cellular efficacy was 
not likely to be caused by toxicity. However, the cellular glycogen data derived from high 
compound concentrations (i.e., 50 µM and 100 µM) should be analyzed cautiously because 
of the potential cytotoxic effect. 
 
Figure 23. Effect of metformin and isoflavones on cell viability. Metformin (A) and the 
five isoflavones (i.e., IF15, IF20, IF23, IF29, and IF36) (B) were incubated in HEK293-
PTG cells for 24 hours to evaluate their cytotoxicity using WST-1 assay. The data represent 




B.  Discussion 
Excess glycogen accumulation in cells leads to impaired autophagy and 
glycophagy, dysregulated mitochondrial metabolism, and eventually cell death. These 
defects are pathological for a number of GSDs. Accumulating evidence suggests that 
suppression of glycogen accumulation through inhibition of GS, the rate-limiting enzyme 
in glycogen biosynthesis, is therapeutically effective for treating various types of GSDs. 
For instance, knocking out GYS1 in Pompe disease mouse models led to significant 
improvement of metabolic and neurologic defects113. Similar results were observed in LD 
mouse models where genetic depletion of GYS1 alleviated LB formation and epileptic 
symptoms63,85. Silencing GYS2 expression using an RNAi approach also effectively 
prevented hepatomegaly and hepatic steatosis in mouse models of Cori and Von Gierke 
disease, respectively88. These results demonstrated that GS is a therapeutically viable target 
without obvious organismal toxicity.  
An FP assay for the screening of small molecule inhibitors of GS was developed in 
our laboratory. The FP assay utilized a GlcN6P-coupled fluorophore, i.e., GlcN6P-
fluorescein-5-Ex which binds in the G6P allosteric site of GS. This assay was used to screen 
compounds that can displace the fluorophore. A Z’-factor of 0.86 indicated the robustness 
and adaptation of this FP assay for HTS. Through a HTS of 50,000 compounds from the 
ChemBridge DIVERSet chemical library against yGsy2, we identified 110 primary hits by 
setting a Z’-score of -1. Those 110 hits were rescreened against yGsy2 using the orthogonal 
14C-glucose incorporation assay, and the number of hits dropped dramatically to 16 by 




the 16 hits against hGYS1 using the radiochemical assay which identified H23 as the only 
inhibitor. The screening triaging strategy is summarized in Figure 24. 
 
Figure 24. Screening triaging strategy. The high-throughput FP assay was utilized to 
screen 50,000 compounds from ChemBridge DIVERSet library. A Z’ score of -1 was 
applied to identify 110 primary hits from the FP assay. Hit validation was achieved by a 
two-step testing against yGsy2 and then hGYS1 using the radiochemical 14C-glucose 
incorporation assay.   
Notably, there is a relatively low yield of hits when the compounds were examined 
using the FP assay and the 14C-glucose incorporation assay. The loss of hits might lie in 
the nature of these two assay systems, since the FP assay is affinity-based whereas the 
radiochemical assay is activity-based. Thus, it is possible to identify compounds that could 
displace the fluorophore without inducing an effect on enzyme activity. We also noticed 
the poor translation of hits when testing moved from yeast to human GS. One possible 




instance, the impact of regulatory input on the enzymes results in different enzymatic 
outcomes. Regulation of yeast GS by G6P primarily impacts kcat, whereas in mammalian 
systems the impact is primarily on Km for substrate44,114. Thus, the discrepancy in hits 
between yGsy2 and hGYS1 could also be affected by the different manners in which the 
kinetic steps in catalysis are impacted by regulatory input. A more sensitive assay directly 
targeting hGYS1 activity is likely to offer a better screening outcome.  
Unfortunately, the HTS FP assay was not suitable for use on hGYS1. Unlike yGsy2, 
both the uncoupled and GlcN6P-coupled fluorophore bound to hGYS1 (Figure 25). 
However, addition of competitive binders such as G6P, UDP, or short glucose polymers 
were not capable of displacing the fluorophores. These data suggest the fluorophores don’t 
bind to any known sites in hGYS1, such as the G6P allosteric site, glycogen-binding sites, 
or active site. The non-specific fluorophore binding, combined with the fact that hGYS1 
produced in insect cells results in a heavily phosphorylated enzyme that requires very high 
concentrations of G6P for activity measurements, makes the full-length recombinant 
human enzyme unsuitable for an assay designed to displace G6P. Therefore, we used 





Figure 25. Binding of the uncoupled and GlcN6P-coupled fluorophore to hGYS1. FP assay 
was utilized to examine the binding and displacement of fluorescein-5-Ex to hGYS1 by 
G6P (A), maltooctaose, and UDP (B), as well as the binding and displacement of GlcN6P-
fluorescein-5-Ex to hGYS1 by G6P, UDP, and maltotetraose (C). The data represent a 
single measurement for each point. 
Nonetheless, our FP assay provided a novel HTS assay, and did indeed identify a 
competitive inhibitor of UDPG, namely (rac)-2-methoxy-4-(1-(2-(1-methylpyrrolidin-2-
yl)ethyl)-4-phenyl-1H-imidazol-5-yl)phenol (H23), that bound within the active site of 
yGsy2. This outcome was determined by both an X-ray structure and by kinetic studies 
using H23 and analogs developed in a subsequent SAR study. However, the site of binding 
was a surprise to us because the assay was designed to identify small molecules that 
displace G6P binding. Upon close inspection of the known eukaryotic GS structures we 




with Tyr492 stacked against the uracil ring of UDP and His500 forming a hydrogen bond 
with the phosphate moiety of G6P (Figure 26A). Considering this structural proximity and 
the cooperative nature of the structural transitions in GS, it was not surprising that binding 
at one site could transmit structural information to the other site and that under the 
subsaturating conditions of our HTS assay, binding of compounds within the active site 
might promote displacement of the fluorophore from the G6P site. To test this hypothesis, 
I determined whether UDP could competitively displace the tracer molecule, GlcN6P-
fluorescein-5-Ex. Whereas, G6P showed a Kd of 71 μM, which is consistent with the 
published AC50 value of ~100 uM for enzyme activation, UDP was able to partially 
displace the fluorophore, but at concentrations >3-fold over the Ki value for UDP inhibition 
of yGsy2p (Figure 26B). This data lends support to our contention that the G6P and UDP 
sites are structurally linked and binding at one site can influence binding at the other, albeit 
not through direct competition for the same site and at lower binding efficiencies. 
 
Figure 26. Displacement of fluorophore through active site inhibitors. (A) Structural 
overview of the binding sites for allosteric activator G6P and substrate UDPG. The UDP 
and G6P binding sites lie on opposing ends of the same alpha-helix (orange), with Tyr492 
contacting the uracil ring of UDP (green) and His500 contacting the phosphate of G6P 
(magenta). (B) Displacement of GlcN6P-fluorescein-5-Ex by UDP in FP assay. The data 




Our focused medicinal chemistry effort with around 500 analogs showed stepwise 
improvement of potency toward wild-type hGYS1 (Figure 27). Although none of the 
imidazole and pyrrole compounds displayed large changes in potency, the pyrazole and 
isoflavone scaffolds demonstrated significant improvement of potency. Remarkably, the 
most potent pyrazole compound, PZ23, showed over 300-fold improvement of potency 
over H23, and the most potent isoflavone compound, IF9, showed over 500-fold 
improvement of potency, compared with the IC50 value of H23. Those newly developed 
pyrazoles and isoflavones both possess a catechol substructure, a chemical moiety that 
appears as a promiscuous compound in many biochemical HTS115. Catechol could undergo 
reversible redox reaction to form 1,2-benzoquinone, presenting toxicity issues. 
Nonetheless, detailed kinetic, enzyme mutagenic, and SAR studies validated those 
pyrazoles and isoflavones are actual inhibitors of GS. Those data provide valuable 
information to understand the kinetic and structural mechanisms of GS inhibition upon 
compound binding.        
 
Figure 27. Improvement of potency toward wild-type hGYS1 through SAR studies. 
Medicinal chemistry effort with ~500 analogs showed stepwise improvement of compound 
potency toward wild-type hGYS1. Dose response curves of representative analogs from 





Those potent pyrazole and isoflavone compounds were further tested in cells to 
assess their abilities to suppress cellular glycogen accumulation. Our collaborator, Dr. 
Anna A. DePaoli-Roach developed an assay where cells were first depleted of glycogen 
through starvation, and then replenished with glucose-containing medium to reinitiate 
glycogen synthesis. Simultaneous with glucose refeeding, our inhibitory compounds were 
added during the 6-hour incubation. This starvation-refeeding protocol was designed to 
directly assess the capacity of compounds in suppressing cellular glycogen biosynthesis. 
Surprisingly, at a test concentration of 25 µM, none of the pyrazole compounds showed 
any inhibition of glycogen accumulation. However, several pyrazole compounds were 
capable of suppressing GS activity that are present in the context of cellular lysates with 
comparable inhibition profile shown in the 14C-glucose incorporation assay (Figure 19). 
The data suggest potential cellular permeability or metabolic stability issues that are 
associated with those pyrazoles which warrant further exploration. Nonetheless, the 
cellular assay identified 5 isoflavone analogs that suppressed cellular glycogen 
accumulation by ≥50% at 25 µM (Figure 21). Furthermore, we noticed that all the 
efficacious compounds possess an electron withdrawing -CF3 group at the R4 position of 
the isoflavone scaffold. However, for analogs which have an electron donating -CH3 group, 
or hydrogen at the R4 position, we did not see any reduction of glycogen level, an 
observation consistent with their lower potency toward hGYS1 that may also indicate 
transport or metabolic differences. 
To further validate their cellular efficacy, the 5 most potent isoflavones were re-
examined in cells for concentration-dependent effects. With 6-hour treatment, all 




µM concentration. When compounds were treated for 24-hour in cells, a more profound 
effect on glycogen accumulation was observed (Figure 22). These data suggest that the 
compounds’ cellular efficacy is both dose- and time-dependent. The 24-hour incubations 
showed a rebound effect on glycogen accumulation above 50 µM. One explanation is that 
the compounds became insoluble and precipitated out of solution as a consequence of 
higher concentrations, resulting in lower working concentrations in solution. Secondly, as 
glycogen being the primary intracellular energy source in these experiments, cells may 
trigger some protective mechanisms for glycogen replenishment when levels get too low. 
Future target engagement experiments, such as using biotinylated compounds or cellular 
thermal shift assays, will be necessary to investigate whether those isoflavones induced 
cellular efficacy through binding directly to GS, or through off-target effect that in turn led 















IV. Discovery and characterization of small molecule inhibitors from a coupled 
GS activity assay adapted to HTS 
Glycogen synthase activity can be analyzed by either following glucose 
incorporation into glycogen as one product of the enzymatic reaction, or you can follow 
the production of the other product, UDP. Over 50 years ago, coupling the phosphorylation 
of UDP from phosphopyruvate via the enzyme pyruvate kinase to either the oxidation of 
NADH, which can be measured spectrophotometrically or fluorometrically, or the use of 
dinitrophenylhydrazine, a colorimetric reagent that acts on pyruvate, was used to measure 
the amount of UDP produced116,117,118. Alternatively, the hydrolysis of UDP by inosine 
diphosphatase-generated Pi could be measured via molybdate-based assays116,119. 
Consequently, it is likely that following either the phosphorylation of UDP or its hydrolysis 
to UMP and Pi provides a better strategy to develop an HTS assay for hGYS1 activity, 
since it is produced stoichiometrically with glucosyl transfer to glycogen. To achieve this 
approach, we utilized a novel, well-characterized human nucleotidase to generate inorganic 
Pi from UDP. The human soluble calcium-activated nucleotidase-1 (hSCAN-1) is an 
apyrase enzyme that hydrolyzes nucleotide di- and triphosphate, with guanosine 
diphosphate (GDP)/UDP/inosine diphosphate (IDP) as the preferred substrates to their 
respective mono-phosphates120. In the defined in vitro assay for GS, there is only UDP 
present and its production will increase as a function of GS activity. Importantly, hSCAN-
1 does not hydrolyze its product UMP. Therefore, the amount of Pi produced should be 
stoichiometric with the amount of UDP generated during the GS reaction, and by extension, 
would equal the amount of glucose incorporated into glycogen. By coupling this hSCAN-




targeting hGYS1 directly. This assay was developed and optimized by Dr. Anna A. 
DePaoli-Roach and deployed by Dr. Cynthia A. Morgan in an HTS assay. I will review the 
optimization of conditions for the HTS assay and its successful application for the 
identification of small molecule modulators of hGYS1 from a 10K chemical library. I will 
also then summarize the work I performed to characterize the hits identified from this 
screen using various biochemical, biophysical, and cellular assays. 
A.  Results 
1. Assay development 
With UDP being one product of the GS reaction and the availability of UDPase 
hSCAN-1, the development of such an assay based on UDP hydrolysis and Pi 
quantification becomes feasible. Under ideal conditions, the amount of inorganic 
phosphate produced should be equivalent to the amount of UDP released as glucose is 
added to glycogen. The HTS assay contained four major steps: 1) the GS reaction where 
UDPG serves as the glucosyl donor to glycogen and releases the product UDP; 2) heat 
inactivation of the GS enzyme; 3) addition of hSCAN-1 to hydrolyze UDP to UMP and Pi; 
and 4) the quantification of Pi present using the Pi ColorLock Gold Assay (Figure 28). Key 
objectives for optimizing the GS reaction conditions were: 1) concentrations of UDPG and 
G6P; 2) enzyme concentration to keep the reaction within the linear range of Pi detection; 
and 3) selecting an incubation time to hold substrate consumption to less than 15-20% of 
available UDPG. Items 2 and 3 are co-dependent variables, since selection of one 
influences the choices for the other. For HTS, we utilized the truncated form of hGYS1, 
hGYS1Δ634S8,11N, for screening purposes. This modified hGYS1 enzyme can be 




under standard assay conditions, which provided a more suitable screening assay since the 
target enzyme was neither overly inhibited due to phosphorylation, nor rendered insensitive 
to the effects of G6P. 
 
Figure 28. Development of high-throughput coupled GS activity assay. A four-step 
procedure is featured in this assay, including (1) GS catalytic reaction, (2) heat inactivation 
of the GS enzyme, (3) hydrolysis of UDP to UMP and Pi via the hSCAN-1 enzyme, and 
(4) quantification of Pi via ColorLock Gold Assay. (This assay was developed by Dr. Anna 
A. DePaoli-Roach.) 
We first examined the half-maximal activity values for both UDPG and G6P using 
the standard 14C-glucose incorporation assay by varying one component while using 
saturating amounts of the other. The Km value for UDPG was 270 ± 60 µM, and the AC50 
value for G6P was 337 ± 24 µM. Based on these values, we utilized 200 µM UDPG and 
400 µM G6P in the screening assay. Varying amounts of glycogen were present in our 
hGYS1Δ634S8,11N enzyme preparations and we noted no change in enzyme activity 
whether we added additional glycogen or not. Therefore, for the HTS we used 1 mg/mL 
glycogen. Once the substrate parameters were established, linearity versus enzyme 
concentration was determined for the enzyme preparation. Although it was in the upper 
linear range of enzyme concentration, a concentration of 1 µg/ml was selected to enable 
the identification of both inhibitors and activators, while still producing a robust signal 




time, with 20 minutes at 30°C allowing for approximately 20% UDPG utilization or less. 
Complete inactivation of GS after the 20 minutes reaction was necessary to prevent 
additional UDP production. In a 1.5 mL microcentrifuge tube, complete inactivation of GS 
occurred by heating in a water bath for 5 minutes at >80°C. In order to get complete and 
nearly even inactivation across a 384-well plate, we used a humidified chamber within a 
hybridization oven at >90°C for 15 minutes, resulting in enzyme inactivation. Although 
the outside rows and columns heated faster, there was very little difference in overall 
enzyme activity between the interior, and exterior wells on the plate, and thus little to no 
edge effects were observed.  
Further analysis of the substrate selectivity for hSCAN-1 was conducted to verify 
previous results that indicated the enzyme’s selectivity for UDP compared to the other 
components present in the assay mix100,120,121. In particular, using HPAEC, we verified that 
hSCAN-1 did not hydrolyze UDPG, UMP, or G6P to any measurable degree, whereas 
CIAP was able to generate Pi (Figure 29). The hSCAN-1 enzyme hydrolyzed UDP to 
UMP. Most critically, there was no hydrolysis of UMP, and therefore no additional Pi 
release in the presence of hSCAN-1. CIAP was able to liberate Pi from both UDP and UMP 
that went untouched by hSCAN-1. In a similar manner, G6P did not liberate an appreciable 
amount of Pi in the presence of hSCAN-1, but glucose was detected in G6P incubated with 
CIAP; thus, any Pi released from G6P or glycogen would also be present in the background 
measurement. To best measure GS activity, we wanted all of the UDP produced in the GS 
reaction to be hydrolyzed by hSCAN-1 to UMP and Pi. Therefore, this step in the assay 
was optimized to ensure the reaction went to completion. Using HTS assay conditions, 10 




the HTS, we selected 61.6 ng/mL hSCAN-1 for 60 minutes to ensure over 99% of UDP 
present was hydrolyzed.  
 
Figure 29. HPAEC analysis of hSCAN-1 activity. UMP, UDP, and UDPG were incubated 
with either hSCAN-1 or CIAP. Only UDP was hydrolyzed by hSCAN-1, whereas CIAP 
was able to hydrolyze both UMP and UDP. UDPG was not affected by either enzyme. 
(This data was generated by Dr. Christopher J. Contreras.) 
The Pi ColorLock Gold assay was used to quantify the amount of Pi produced from 
UDP through the hSCAN-1 enzymatic reaction. This highly sensitive assay was able to 
detect the low nanomoles of Pi released in our HTS assay. The standard curve for Pi 
indicated that the assay was linear up to 3.5 nanomoles, but began to saturate above that 
point. Based on our assay components, the maximum amount of Pi that could be produced 




consumed. However, we optimized the conditions such that for the control, approximately 
20% UDPG was utilized, and therefore the control reactions should produce approximately 
1.6 nanomoles of Pi, well within the linear range of the Pi ColorLock Gold assay. As such, 
this assay would identify both activators and inhibitors and could distinguish between a 
90% inhibitor and a 50% inhibitor, but it would not distinguish a 2-fold activator from a 5-
fold activator. 
For confirmation of the quality of the HTS protocol to identify hGYS1 modulators 
from a single replicate, a Z’-factor score was calculated to compare the no-hGYS1 positive 
controls (i.e., maximum inhibition) versus the DMSO negative controls. The Z’-factor of 
0.84 between the positive and negative controls indicated this assay would be very effective 
at identifying hGYS1 inhibitors (Figure 30). 
 
Figure 30. Z’-Factor determination for high-throughput coupled GS activity assay. Each 
point represents the absorbance value at 650 nm of a reaction. Green data points represent 
the assay control. Black data points represent the no hGYS1 control. Red data points 
represent the no-G6P control. The corresponding lines represent 3× standard deviation 
from each control average. The Z’-factor for the control versus no hGYS1 control is 




2. Compound screening from 10K chemical library 
As proof-of-principle for the HTS assay, Dr. Cynthia A. Morgan screened a 10,000-
compound library comprised of known drugs, bioactives, and natural products. Primary 
hits were selected as those compounds exhibiting ≥25% inhibition or ≥40% activation 
compared to the intraplate controls. All hits were also outside of 3× standard deviation 
from the control average established for each plate. Approximately half of the plates 
contained at least one compound that met our selection criteria. Primary screening in 
singlicate identified 60 inhibitors and 59 activators. These 119 compounds were then 
cherry-picked and re-tested in duplicate. Selection criteria for activators remained at ≥40% 
activation, while a more stringent criteria of ≥ 40% inhibition was used to identify 
inhibitors. Of the 119 cherry-picked compounds, 3 activators and 46 inhibitors remained 
after the second round of screening. Overall the HTS gave a hit rate of approximately 1% 
after primary screening, with over one-third of these hits re-confirmed in secondary 
screening. These 49 unique compounds identified in the HTS as modulators of 
hGYS1Δ634S8,11N represent a diverse spectrum of compounds and included opioids, 
anti-parasitics, ion-channel blockers, and dyes. The largest group contained flavonoids, 
including epigallocatechin-3-monogallate (EGCG), gossypol, katacine, and 6,2’-
dimethoxyflavone. Various anti-parasitics and disinfectants including hexachlorophene 
(HCLP), closantel, and tetracycline were also identified.  
3. Titration experiments with selected HTS hits 
Of the 46 inhibitors, 6 hits were ordered to validate whether the identified 
compounds also inhibit GS using the standard 14C-glucose incorporation assay. These 




acid (DIDS), tetracycline, and zonisamide, which were selected based on their degree of 
inhibition during re-screening, commercial availability, and diversity of scaffold. We first 
tested these compounds on both wild-type hGYS1 and hGYS1Δ634S8,11N at a single dose 
of 20 µM. Tetracycline and zonisamide were weak inhibitors in the HTS and showed little 
to no inhibition on either the WT-hGYS1 or the truncated enzyme using the radiochemical 
assay. The remaining four compounds inhibited both of these enzymes, ranging from ~30% 
inhibition of wild-type hGYS1 with HCLP to ≥95% inhibition of both enzymes with 
EGCG (Figure 31A). This data showed comparability of inhibition to both enzyme species 
of hGYS1, demonstrating the effectiveness of using hGYS1Δ634S8,11N as a screening 
surrogate for wild-type hGYS1. IC50 curves were produced for each of these four 
compounds using the hGYS1 WT. Their values ranged from 1.5>0.3 µM for DIDS to 
21.5>1.9 µM for HCLP (Figure 31B). I further examined mode of inhibition of two 
compounds through titration experiments by co-varying UDPG and inhibitor 
concentrations using the 14C-glucose incorporation assay. As demonstrated in the 
Michaelis-Menten curves, EGCG was a noncompetitive inhibitor (Ki = 23.1>1.0 μM) 
whereas HCLP was a mixed-type inhibitor versus UDPG (Ki = 25.2 > 7.8 μM) (Figure 
31C). The higher Ki value EGCG produced in the titration assay than its IC50 value 
(2.8 > 0.4 µM) derived from the dose-response assay was likely caused by different 
glycogen concentrations (6.7 mg/ml versus 1 mg/ml) in the assays, which was further 





Figure 31. Titration experiments with selected HTS hits. (A) Effect of HTS hits on hGYS1 
WT and hGYS1Δ634S8,11N. A single dose of 20 µM of each compound was tested on 
both wild-type and mutant hGYS1. (B) Dose response assays were done from 0 to 100 µM 
to determine the IC50 values for EGCG, DIDS, closantel, and HCLP. Each assay contains 
0.2 mM UDPG, 0.4 mM G6P, and 1 mg/ml glycogen. A minimum of three assays (each at 
n=3) were performed for each compound and a representative curve for each compound is 
shown below. The IC50 value shown is the average ± SEM for all assays. (C) Mode of 
inhibition of EGCG and HCLP against wild-type hGYS1. Each assay contains saturating 
G6P (7.2 mM) and glycogen (6.7 mg/ml) concentrations. The reported Ki values are the 
mean ± SEM from three independent experiments in duplicate. 
4. Kinetic characterization of EGCG 
As EGCG showed a noncompetitive inhibition mode versus UDPG, we 
hypothesize EGCG may bind to glycogen-binding sites on GS since it has multiple 
hydroxyl groups that could competitively displace glycogen, which is also rich in 
hydroxyls. Four glycogen-binding sites (designated S1/S2/S3/S4) have been identified 




residues in contact with maltodextrin binding on site 1 (S1A3, W118A/W149A/H156A) 
decreased in vitro GS catalytic efficiency by 40-fold and cellular glycogen accumulation 
by 6-fold40. I examined the potency of EGCG toward the S1A3 enzyme and determined 
that EGCG showed a 23-fold reduction in potency toward S1A3 (Figure 32A. Whether 
EGCG impacts binding at other glycogen-binding sites needs further investigation. The 
similarity in IC50 values derived from different G6P concentrations makes it less likely that 
EGCG interacts near the G6P site (Figure 32A). Additionally, two structurally similar 
analogs of EGCG, epigallocatechin (EGC) and epicatechin (EC), were examined for their 
potency to yGsy2. While EGCG had an IC50 value of 6.62 µM, EGC showed a 2-fold 
decrease of potency, whereas EC showed no inhibition to yGsy2 (Figure 32B). This data 
further supports the idea that the number of hydroxyl units on these green tea extracts could 
play a key role in conferring inhibition toward GS.  
 
Figure 32. Kinetic characterization of EGCG. (A) Dose response curves of EGCG to wild-
type yGsy2 and S1A3 mutant in the absence or presence of 7.2 mM G6P. (B) Dose-
response curves of EGCG, EGC, and EC to wild-type yGsy2 in the absence of G6P. The 




5. Structural and kinetic characterization of HCLP 
To understand how compounds physically interact with GS, I used X-ray 
crystallography in an attempt to determine the structure of the HCLP-enzyme complex. 
The structural data and refinement statistics are outlined in Table 6. The presence of HCLP 
was confirmed by 2Fo-Fc map contoured at 1 standard deviation prior to the inclusion of 
ligand (Figure 33A). I superposed this yGsy2p (WT)-HCLP structure with the yGsy2p-
UDP•G structure (PDB code: 4KQM) in the active site, and found that UDPG and HCLP 
existed in somewhat overlapping, yet distinct, binding modes. As shown in the cartoon 
representation, UDPG and HCLP bound in orthogonal orientations within the GS active 
site (Figure 33B). A close inspection of the binding structure revealed that HCLP was   
Table 6. Structural data and refinement statistics for HCLP-yGsy2p crystal. 
Data collection Refinement 
Space group I222 No. reflections 68635 
Cell dimensions  Rwork/Rfree 0.20/0.26 
a, b, c (Å) 191.7, 203.5, 205.3 r.m.s. deviations  
α, β, γ 90.0, 90.0, 90.0 Bond lengths (Å) 0.01 
Resolution (Å) 50-3.15 Bond angles (º) 1.8 
Rmerge 0.125 (0.77) Ramachandran plot  
Rmeas 0.141 (0.870) Preferred/Allowed (%) 98.7 
Rpim 0.065 (0.406) Outliers (%) 1.3 
CC1/2 0.999 (0.761) B-factors  
I/σ(I) 12.4 (1.9) Protein Chain A, 73.8; B, 81.2; 
C, 87.9; D, 89.9 Completeness (%) 99.5 (99.2) 







Figure 33. Characterization of HCLP. (A) The electron density for HCLP prior to the 
inclusion of the ligand in refinement. The map shown is the original unbiased 2Fo-Fc map 
contoured at 1 standard deviation. (B) Stick representation of the superposed UDP•G 
(purple) and HCLP (yellow) structures in the active site of GS. (C) Molecular interactions 
of HCLP with surrounding residues. (D) Inhibition of HCLP to WT, S26A, and Y513L 
mutants of yGsy2. (E) Inhibition of HCLP to WT, the basal state mutant (R580A3), and 
the inhibited state mutant (R589A2) of yGsy2. (F) Dose response curves of HCLP against 




mainly stabilized by hydrophobic interactions, including one phenyl ring (P1) being 
stabilized by π- π stacking with Phe480, Tyr492, and Tyr513, while the other ring (P2) is 
stabilized by aromatic interactions with Phe480 and Arg20. The chlorines formed to form 
multiple hydrophobic interactions with Val21, Ala318, Gly319 as well as polar interactions 
with Ser26, Thr514, and Glu517. Additionally, the hydroxyl group on P2 was in close 
contact with GS and was likely to form a hydrogen bond with Ser26. The two hydroxyl 
groups were also in close proximity (2.4 Å) and appeared to form an intramolecular 
hydrogen bond, which maybe critical for keeping the two aromatic rings in a relative planar 
conformation122 (Figure 33C). 
To understand the molecular interactions that confer HCLP binding to GS, enzyme 
mutagenic studies were performed to examine two key residues predicted to be important 
for binding. The Ser26 hydroxyl is 2.45 Å from the hydroxyl group of the P2 ring and 
putatively forms a hydrogen bond, and the Tyr513 side chain oriented more inwardly into 
the binding pocket in the HCLP-bound conformation to facilitate parallel π-stacking 
interaction with the P1 ring. While HCLP inhibited the S26A mutant nearly equipotently 
as wild-type yGsy2, it exhibited a 4-fold reduction of potency against the Y513L mutant 
(Figure 33D). These data suggest that the hydrophobic interactions, rather than hydrogen 
bonds, were most important for the binding of HCLP in the catalytic site. 
Next, I validated the binding of HCLP in the active site by testing its inhibition 
against different activity-state mutants of yGsy2, including the basal state mutant R580A3 
and the inhibited state mutant R589A2. Compared with the basal state mutant, HCLP 
showed less inhibition to the inhibited state mutant (Figure 33E). When tested under 




was increased from 0, 7.2 mM, to 30 mM (Figure 33F), indicating the more activated the 
enzyme is, the better potency HCLP produces. Taken together, these data clearly 
demonstrated that HCLP is an active-site interactor of GS. 
6. SAR for HCLP analogs 
I further probed the SAR profile of HCLP using 15 structurally similar analogs 
(designated as HC1-HC15), and tested their inhibition against GS. These analogs showed 
comparable inhibitory effect across yeast and human GS species (Table 7). Among these 
analogs, compound HC1 (bithionol) demonstrated the greatest potency against hGYS1. 
Bithionol has two fewer chlorines than HCLP in the meta positions and a sulfur atom 
linking the two aromatic rings. When this sulfur was replaced by sulfur monoxide, I 
observed a 3-fold decrease of potency to hGYS1 (HC1 versus HC3), possibly due to 
increased steric hindrance or conformational constraints caused by the sulfur monoxide. 
Compound HC4 has two less chlorines at the ortho positions compared with bithionol, and 
showed around 5-fold decrease in potency. Analog HC2 has two bromines instead of 
chlorines at the ortho positions, and a carbon instead of sulfur between the two aromatic 
rings, which exhibited more than 2-fold decrease of potency compared with bithionol. 
Additionally, removal of the two bromines further reduced inhibitory effect (HC2 versus 
HC5). Since both aromatic rings form hydrophobic interactions in the active site, I 
hypothesize that the chlorines function as electron-withdrawing groups to improve stacking 
interactions123. Consequently, loss of chlorines or substituting chlorines with bromines 
diminish this electron-withdrawing effect, and lead to decreased binding efficiency and 




HCLP seems to be critical to confer inhibition, as compounds HC7-HC13 totally abolished 
inhibition at 25 μM when either hydroxyl group was absent.  







NI: no inhibition up to 1 mM; ND: not determined. Values are the mean ± SEM from at 
least three independent experiments in duplicate. 
7. Analysis of HCLP and its analogs in cells  
As a proof-of-principle study, we selected three compounds to further examine their 
ability to suppress glycogen accumulation in the engineered HEK293-PTG cell-based 
assay. These compounds were HCLP, HC1 (bithionol), and their counterpart compound 
HC3 (bithionoloxide), which were selected based on their comparable potency to hGYS1 
and structural similarity. Using the starvation-refeeding protocol described earlier, I 
observed dose-dependent inhibition of glycogen accumulation when HEK293-PTG cells 
were treated with increasing concentrations of HCLP and bithionol, but not bithionoloxide 
(Figure 34A). To further validate their cellular effects, I tested the compounds in Rat-1 
fibroblast cells. Rat-1 fibroblast cells demonstrated measureable GS activity31,106, and 




for bithionoloxide, both HCLP and bithionol reduced glycogen accumulation in a dose-
dependent manner, an observation consistent with the cellular efficacy as shown in 
HEK293-PTG cells (Figure 34B). To understand whether the decreased glycogen 
accumulation was associated with cellular toxicity, the WST-1 assay as described 
previously was performed to assess cell viability. HEK293-PTG cells were incubated with 
three concentrations (10 μM, 25 μM, and 50 μM) of HCLP, bithionol, and bithionoloxide 
for 24 hours. As the results indicated, HCLP did not show cellular toxicity at 10 μM, 
whereas bithionoloxide did not show any cellular toxicity even at 50 μM concentration 
(Figure 34C). While HCLP and bithionol were effective at reducing glycogen levels in 
cells, these results suggest these effects may relate primarily to the cytotoxicity of these 
compounds to cells; however, further studies are warranted on a larger set of analogs to 
make more definitive conclusions. 





Figure 34. Analysis of HCLP, bithionol, and bithionoloxide in cells. Concentration-
dependent response for HCLP, bithionol, and bithionoloxide in HEK293-PTG (A) and Rat-
1 (B) cells. Compounds were incubated for 6 hours. The data represent averages of 
triplicate assays ± SEM. (C) Effect of HCLP, bithionol, and bithionoloxide on cell 
viability. The three compounds were incubated in HEK293-PTG cells for 24-hour to 









B.  Discussion 
In this section, I demonstrated how our laboratories developed a nonradioactive 
high-throughput assay for the identification of small molecule modulators of human GS 
activity. In this assay, glycogen catalytic activity is coupled to the production of UMP and 
Pi. It is worth noting that there may not be an exact 1:1 relationship between glucose 
incorporated into glycogen and the Pi measured. UDPG can be non-productively 
hydrolyzed to glucose and UDP without successful transfer of the glucose residue into 
glycogen, yet this reaction still produces UDP. However, comparison of this assay with the 
standard 14C-glucose incorporation assay suggests that, in general, this non-productive 
turnover of UDPG is low and where a large difference is observed, may offer insight into 
how the compound is impacting enzyme catalysis. Modulators of hSCAN-1 could also be 
identified via the HTS, even though a saturating hSCAN-1 enzyme concentration (61.6 
ng/mL, 6 times than needed) was used in the assay. Based on the results with zonisamide 
and tetracycline, these compounds may have an effect on hSCAN-1, since both had modest 
inhibition using this HTS assay but little to no inhibition in the 14C-glucose incorporation 
assay. In this regard, the orthogonal 14C-glucose assay serves as an effective validation 
assay for the discrimination of false positive hits that target hSCAN-1. 
Using this assay, we identified 46 inhibitors of hGYS1. This 10K chemical library 
consisted of drugs, natural products, and semi-synthetic natural compounds. As many hits 
included large polyphenols such as tannins, theaflavin mono- and digallates, the stains 
hematein and gentian violet, plus the metal chelator dimercaptosuccinic acid, and have 
been recognized as pan-assay interference compounds (PAINS – e.g. EGCG, gossypol, and 




still prove useful as molecular probes to study GS structure, function, and inhibition. 
Various drugs were also identified in the HTS, including the antimicrobials tetracycline, 
closantel, HCLP, ion channel blockers including calmidazolium chloride and DIDS, plus 
the thyroid hormone analog tiratricol. Most of these drugs are known to affect multiple 
biological pathways and most are not approved for use in humans by the FDA. 
Interestingly, this assay also identified 3 small molecule activators of human GS. Although 
their activation has not been validated through dose response assay or 14C-glucose 
incorporation assay, once confirmed these molecules would be of great interest to be 
studied further for their mechanism of activation, binding mode, affinity, etc.     
Despite the nature of this compound library, results from 14C-glucose incorporation 
assay confirmed that EGCG, HCLP, closantel, and DIDS inhibit human GS with low 
micromolar IC50 values (Figure 31B). Kinetic snalyses showed EGCG and HCLP are 
noncompetitive and mixed-type inhibitors against hGYS1, respectively (Figure 31C), 
demonstrating the capacity of this assay for finding compounds with different binding 
modes. Such an outcome was expected since this high-throughput coupled assay was an 
activity-based approach; thus, any compounds that could decrease GS activity by blocking 
glycogen-, UDPG-, or G6P-binding, either competitively or allosterically, would be 
identified. To further validate whether the primary hits were true GS-binders, a crystal 
structure of HCLP-complexed with yGsy2 was obtained, which unambiguously identified 
HCLP bound in the catalytic cleft of GS. Enzyme mutagenic data, along with SAR studies, 
lend further support to such a binding mode (Figure 32, Table 7). These biochemical and 
biophysical studies together confirmed the hits derived from this high-throughput 




Consistent with their comparable potency toward hGYS1 in the 14C-glucose 
incorporation assay, both HCLP and bithionol exhibited dose-dependent inhibition of 
glycogen accumulation in two cell lines, whereas bithionoloxide did not (Figure 33). 
However, HCLP and bithionol were found to be generally cytotoxic to HEK293-PTG cells, 
which could be the driving factor in glycogen reductions. This may not be surprisingly 
since they are known to affect a number of intracellular proteins126,127,128 and trigger 
pleiotropic biological activities, including antiviral129 and anticancer130,131,132 effects. 
HCLP was once widely used as a disinfectant, anti-bacterial agent in medicine and 
bactericide in agriculture. Further animal and clinical studies indicated the application of 
HCLP was associated with the development of specific lesions in the CNS133. However, 
the alternative organochlorine, bithionol, does not appear to damage the CNS and was 
suggested as a possible substitute for HCLP134. In fact, bithionol has received approval 
from Food and Drug Administration as an orally administered medication for the treatment 
of helminthic infections and has been safely dosed in humans at 25 mg/kg body weight per 
day135. The drug has also proven to be effective in preclinical cancer models and safe in 
non-cancer patients131. Detailed toxicology and pharmacokinetics of bithionol are available 
at Toxnet (U.S. National Library of Medicine). Although the polypharmacology of HCLP 
and bithionol makes them unsuitable for drugs toward GSDs, the unique binding pattern, 
mechanism of inhibition, and SAR studies provide important insights for the further 
development of GS-modulating drugs. 
In summary, this 10K HTS yielded 119 primary hits, possessing a hit rate of around 
1%. Rescreening of those 119 hits validated 49 hits, including 46 inhibitors and 3 




using the 14C-glucose incorporation assay, selected based on degree of inhibition during 
rescreening, availability, drug-like properties, and diversity of scaffold. As a consequence, 
4 out of the 6 compounds showed the desired biochemical effect, i.e., with low micromolar 
potency to wild-type hGYS1. Compared with the high-throughput FP assay, this high-
throughput coupled assay presented a few advantages. Firstly, this assay was designed to 
screen for inhibitors of human GS directly, rather than yeast GS. Secondly, in our 
pioneering studies, two thirds of hits were validated in the standard radiochemical assay, 
demonstrating a good transition of hit rates between these two assays, whereas the FP assay 
demonstrated a relatively low transition (14.5%) to 14C-glucose incorporation assay. 
Thirdly, only 14 nM hGYS1 enzyme was needed to achieve a measurable signal in the 
HTS assay, while in the FP assay 3 µM yGsy2 enzyme was used. The high-throughput 
coupled activity assay thus demonstrated a great improvement in assay sensitivity. Based 
on these observations, we conclude that this novel, two-step enzymatic, and colorimetric 
assay is capable of identifying small molecule modulators of human GS. This assay is 
rapid, robust, and nonradioactive, representing a marked improvement over the current 
radiochemical method for the identification of lead compounds. Based on these results, we 
are confident that our novel high-throughput coupled activity assay with human GS can be 









V. Conclusions and future directions 
The suppression of glycogen accumulation has emerged as an attractive therapeutic 
approach for GSDs whose etiology is derived from excessive glycogen accumulation. 
Animal models support an approach where genetic or chemical depletion of glycogen in 
mouse models of Lafora disease63,84,85,86,136, of Pompe disease87, and of Cori disease 
alleviates the disease symptoms88. Interestingly, recent studies suggested that T2D might 
also possess disease characteristics similar to some GSDs, such as glycogen accumulation 
in pancreatic β cells under hyperglycemic conditions contributing to β-cell dysfunction62,70.  
Only a few studies have identified molecules that target glycogen accumulation, 
including the widely-used glucose lowering T2D drug metformin108,111, the mTORC1 
inhibitor, rapamycin, that indirectly suppress GS activity through signaling regulation87, 
use of RNAi to mediate reduction of GYS288, and a newly developed antibody-enzyme 
fusion that can directly degrade polyglucosan136. However, these molecules either targeted 
glycogen synthesis in an indirect manner, or presented a separate challenge for the delivery 
of the therapeutic to the central nervous system. Here, we have established two robust, 
rapid, and nonradioactive methods as HTS vehicles for the discovery, characterization, and 
development of small molecule inhibitors of GS. 
In our first approach, we adopted a high-throughput FP assay to screen for small 
molecule inhibitors that can displace a G6P-coupled fluorophore that binds to the allosteric 
site of yGsy2. Screening the ChemBridge DIVERSet library which contains 50,000 
compounds yielded 110 primary hits, and through the 14C-glucose incorporation assay only 
1 hit (H23, (rac)-2-methoxy-4-(1-(2-(1-methylpyrrolidin-2-yl)ethyl)-4-phenyl-1H-




both an X-ray structure and by kinetic studies using H23 and analogs as part of a robust 
SAR study. The binding at the UDP site was surprising because the assay was designed to 
identify small-molecule inhibitors that displaced G6P binding. However, a close inspection 
of the known, eukaryotic GS structures demonstrates that the UDPG and G6P binding sites 
resided on opposing ends of the same alpha-helix, with Tyr492 stacked against the uracil 
ring of UDP and His500 forming a hydrogen bond with the phosphate moiety of G6P. 
Considering this direct structural linkage and the cooperative nature of the structural 
transitions in GS, it was not surprising that binding at one site could transmit structural 
information to the other site and that under the subsaturating conditions of our HTS assay, 
binding of compounds within the active site could promote displacement of the fluorophore 
from the G6P site. This was further confirmed by the observation that UDP can displace 
the fluorophore at high concentrations (Figure 26B). 
Extensive medicinal chemistry efforts led to the identification of potent analogs 
with low micromolar potency to hGYS1 possessing two chemical scaffolds, i.e., pyrazole 
and isoflavone. Representative compounds from each scaffold, PZ23 and IF9, 
demonstrated over 300- and 500-fold marked improvement of potency compared with the 
potency of parent compound H23. Mode of inhibition and enzyme mutagenic studies 
suggested these analogs bind in the active site of GS with similar binding mode of H23. 
Based on the existing data, manual docking of PZ23 and IF9 were performed to model 
their binding. Considering the multiple activity states and dynamics of GS conformation, 
obtaining crystal structures of ligand-enzyme complex is necessary to further understand 
the molecule interactions conferring binding. Particularly, isoflavones, a class of 




accumulation. This encouraging data validated our biochemical and medicinal approaches 
for the development of small molecule inhibitors as a means to suppress cellular glycogen 
accumulation. 
Due to the poor outcome and low translation of the high-throughput FP assay to 
14C-glucose incorporation assay, we sought an alternative HTS approach by developing a 
coupled colorimetric assay for the identification of small molecule modulators of hGYS1. 
The second assay, based on malachite green detection of Pi, was designed to measure UDP 
production derived from UDPG following glucosyl transfer. The specificity of hSCAN-1 
to hydrolyze UDP to UMP and Pi played a key role in the successful implementation of 
this coupled assay in a high-throughput fashion. An excellent Z’-factor of 0.84 
demonstrated the robustness of this screening assay. In proof-of-principle for this HTS 
assay, we screened 10,000 compounds from the ChemBridge Microsource library from 
which we identified and validated four compounds with micromolar potency toward 
hGYS1. The high sensitivity, translatability, and reproducibility of this high-throughput 
coupled assay demonstrated great improvement over the FP assay as a HTS platform for 
the identification of small molecule modulators of human GS.            
Humans have two isoforms of GS, namely hGYS1 and hGYS2. The fact that 
hGYS1 is universally expressed in most tissues while hGYS2 is restrictively expressed in 
liver prompted us to identify inhibitors against hGYS1 in the hope of diminishing brain 
glycogen stores, aberrantly accumulated in some GSDs such as Lafora disease53. The high 
sequence homology between hGYS1 and hGYS2 enzymes could make it difficult to 
develop isoform-specific inhibitors. Nonetheless, inhibition of hGYS2 might aid in the 




ultimately lead to liver damage. Recently, Pursell et al. showed that GYS2 inhibition with 
RNAi prevents liver injury in mouse models of Corwedisease and had no adverse effects88.  
Mutations in GYS1137 or GYS2138 in rare GSDs lead to decreased glycogen in 
muscle and liver respectively. Disruption of the mouse GYS1 gene resulted in 90% 
perinatal lethality, likely due to cardiac developmental problems during embryogenesis, 
but the surviving mice were ostensibly normal and lived normal lifetimes139. Disruption of 
GYS2 in mice largely mimicked the phenotype of human GSD0 patients, namely 
tendencies to post-prandial hyperglycemia and to hypoglycemia upon fasting but 
compatible with a relatively normal life138,140. Given that small molecule inhibition will not 
have the penetrance of genetic defects, inhibition of GS activity by small molecules is 
unlikely to elicit extreme phenotypes, and small-molecule inhibition remains as a 
potentially valuable means of treating these devastating diseases.  
In summary, this study described two strategies of assay development for the 
screening of small molecule inhibitors of GS, the binding modes of H23 and HCLP 
validated through both X-ray crystallographic and kinetic data; and SAR study leading to 
analogs, such as pyrazole PZ23 and isoflavone IF9, with low micromolar potency. These 
outcomes suggest that targeting GS with small molecule inhibitors represents an attractive 
approach for developing new therapeutics for diseases in the GSD family. Unlike other 
enzyme-based strategies where complete inhibition is the ultimate objective, a partial 
reduction of GS activity may be sufficient to alleviate unwanted and damaging levels of 
glycogen deposition in the neural tissue of patients suffering from Lafora disease63,84,86. 
The challenges of developing any therapeutic, nevertheless, remain the same, and the gulf 




low micromolar range and a therapeutic candidate is wide and deep. Initial efforts will 
involve microsomal studies to evaluate anticipated pharmacokinetic concerns about 
unwanted redox reactions of PZ23 to 4-(4H-pyrazol-4-ylidene)- or 2,3-dihydroxy-4-(3H-
pyrazol-3-ylidene)cyclohexa-2,5-dien-1-ones, or IF9 to 7-, or 8-hydroxy-3-phenyl-4H-
8l5-chromene-4,8-dione. We will use a combination of synthesis (i.e., SAR studies) and 
computational modeling to identify analogs that avoid this concern and retain desired 
physiochemical properties (i.e., water solubility; bioavailability); we will evaluate any 
promising, new leading structures for potential toxicity issues (e.g., hERG studies); and we 
will explore biotinylated analogs to confirm the specificity of these pyrazole analogs for 
the desired target. These initial, encouraging results bode well for the future development 
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